

TEKLA LIFE SCIENCES INVESTORS
Form N-PX
August 20, 2018

**UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION**

OMB APPROVAL
OMB Number: 3235-0582
Expires: March 31, 2021
Estimated average burden
hours per response.....7.2

Washington, D.C. 20549

FORM N-PX

**ANNUAL REPORT OF PROXY VOTING RECORD OF REGISTERED
MANAGEMENT INVESTMENT COMPANY**

Investment Company Act file number **811- 06565**

Tekla Life Sciences Investors

(Exact name of registrant as specified in charter)

100 Federal Street, 19th Floor, Boston, MA
(Address of principal executive offices)

02110
(Zip code)

Laura Woodward

Tekla Life Sciences Investors

100 Federal Street, 19th Floor, Boston MA 02110

(Name and address of agent for service)

Registrant's telephone number, including area code: **617-772-8500**

Date of fiscal year end: **September 30**

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

Date of reporting period: **7/1/17-6/30/18**

Form N-PX is to be used by a registered management investment company, other than a small business investment company registered on Form N-5 (ss.ss.239.24 and 274.5 of this chapter), to file reports with the Commission, no later than August 31 of each year, containing the registrant's proxy voting record for the most recent twelve-month period ended June 30, pursuant to section 30 of the Investment Company Act of 1940 and rule 30b1-4 thereunder (17 CFR 270.30b1-4). The Commission may use the information provided on Form N-PX in its regulatory, disclosure review, inspection, and policymaking roles.

A registrant is required to disclose the information specified by Form N-PX, and the Commission will make this information public. A registrant is not required to respond to the collection of information contained in Form N-PX unless the Form displays a currently valid Office of Management and Budget (OMB) control number. Please direct comments concerning the accuracy of the information collection burden estimate and any suggestions for reducing the burden to the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW, Washington, DC 20549-0609. The OMB has reviewed this collection of information under the clearance requirements of 44 U.S.C. ss. 3507.

Item 1. Proxy Voting Record.

HQL Vote Summary

AC IMMUNE SA

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | H00263105 | Meeting Type | Special |
| Ticker Symbol | ACIU | Meeting Date | 27-Apr-2018 |
| Record Date | 13-Mar-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|-------------|---|--------------------|-------------|-------------------------------|
| 1. | In the event that at the Extraordinary Shareholders Meeting, shareholders or the Board of Directors make additional or amended motions to the published agenda items and/or put forward new motions or in absence of any specific instruction, I/we instruct the independent proxy to vote in respect to such motions as proposed by the Board of Directors | Management | For | N/A |
| 2.A | Election of Douglas Williams as Member to the Board of Directors | Management | For | N/A |
| 2.B | Election of Douglas Williams to the Compensation, Nomination & Corporate Governance Committee | Management | For | N/A |
| 3.a | Vote on Total Non-Performance-Related Compensation for the new Member of the Board of Directors from 27 April 2018 to 30 June 2018 | Management | For | N/A |
| 3.b | Vote on Equity for the new Member of the Board of Directors | Management | For | N/A |
| 4.a | Share Capital Increase for Institutional Investors | Management | For | N/A |
| 4.b | Share Capital Increase for Current Shareholders | Management | For | N/A |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

AC IMMUNE SA

| | | | |
|---|----------------------------------|----------------------------------|-----------------------|
| Security Ticker Symbol Record Date | H00263105 ACIU 23-May-2018 | Meeting Type Meeting Date | Annual 06-Jul-2018 |
|---|----------------------------------|----------------------------------|-----------------------|

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| A. | In the event that at the Annual General Meeting, shareholders or the Board of Directors make additional or amended motions to the published agenda items and/or put forward new motions or in absence of any specific instruction, I/we instruct the independent proxy to vote in respect to such motions as proposed by the Board of Directors | Management | For | N/A |
| 1. | Approval of the Annual Report, Annual Statutory Financial Statements and Financial Statements under IFRS of AC Immune SA for the year 2017 | Management | For | N/A |
| 2. | Appropriation of Loss | Management | For | N/A |
| 3. | Discharge of the Members of the Board of Directors and the Executive Committee | Management | For | N/A |
| 4a. | Vote on Total Non-Performance-Related Compensation for Members of the Board of Directors from 1 July 2018 to 30 June 2019 | Management | For | N/A |
| 4b. | Vote on Equity for Members of the Board of Directors | Management | For | N/A |
| 4c. | Vote on Total Non-Performance-Related Compensation for Members of the Executive Committee from 1 July 2018 to 30 June 2019 | Management | For | N/A |
| 4d. | Vote on Total Variable Compensation for Members of the Executive Committee for the current year 2018 | Management | For | N/A |
| 4e. | Vote on Equity for Members of the Executive Committee | Management | For | N/A |
| 5a. | Re-election of Martin Velasco as member and Chairman of the Board of Directors | Management | For | N/A |
| 5b. | Re-election of Peter Bollmann as the Member of the Board | Management | For | N/A |
| 5c. | Re-election of Friedrich von Bohlen as the Member of the Board | Management | For | N/A |
| 5d. | Re-election of Andrea Pfeifer as the Member of the Board | Management | For | N/A |
| 5e. | Re-election of Detlev Riesner as the Member of the Board including granting an exception to the age limit | Management | For | N/A |
| 5f. | Re-election of Tom Graney as the Member of the Board | Management | For | N/A |
| 5g. | Re-election of Douglas Williams as the Member of the Board | Management | For | N/A |
| 5h. | Election of Werner Lanthaler as the Member of the Board | Management | For | N/A |
| 6a. | Re-election of Tom Graney to the Compensation, Nomination & Corporate Governance Committee | Management | For | N/A |
| 6b. | Re-election of Martin Velasco to the Compensation, Nomination & Corporate Governance Committee | Management | For | N/A |
| 6c. | Re-election of Doug Williams to the Compensation, Nomination & Corporate Governance Committee | Management | For | N/A |
| 7. | Re-election of the independent proxy Bugnion Ballansat Ehrler, represented by Gerald Virieux, avocat, Geneva | Management | For | N/A |
| 8. | Election of the Auditors, PricewaterhouseCoopers SA, Pully | Management | For | N/A |
| 9a. | Share Capital Increase for Institutional Investors | Management | For | N/A |
| 9b. | Share Capital Increase for Current Shareholders | Management | For | N/A |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

ACADIA PHARMACEUTICALS INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 004225108 | Meeting Type | Annual |
| Ticker Symbol | ACAD | Meeting Date | 06-Jun-2018 |
| Record Date | 13-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 | Julian Baker | For | For |
| | 2 | Stephen Biggar, M.D PhD | For | For |
| | 3 | Daniel Soland | For | For |
| 2. | To approve an amendment to our 2010 Equity Incentive Plan, as amended, to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the plan by 6,700,000 shares. | Management | For | For |
| 3. | To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement for the annual meeting. | Management | For | For |
| 4. | To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management | For | For |

ACCELERON PHARMA INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 00434H108 | Meeting Type | Annual |
| Ticker Symbol | XLRN | Meeting Date | 06-Jun-2018 |
| Record Date | 09-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1a. | Election of Class II Director: Habib J. Dable | Management | For | For |
| 1b. | Election of Class II Director: Terrence C. Kearney | Management | For | For |
| 1c. | Election of Class II Director: Karen L. Smith, M.D., Ph.D. | Management | For | For |
| 2. | To approve, on an advisory basis, the compensation paid to the Company's named executive officers as disclosed in the proxy statement. | Management | For | For |
| 3. | To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management | For | For |

ACHILLION PHARMACEUTICALS INC

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 00448Q201 | Meeting Type | Annual |
| Ticker Symbol | ACHN | Meeting Date | 31-May-2018 |
| Record Date | 16-Apr-2018 | | |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---|-----------------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 | Nominee removed | For | For |
| | 2 | Jason Fisherman, M.D. | For | For |
| 2. | To approve, on an advisory basis, our executive compensation. | Management | For | For |
| 3. | To approve an amendment and restatement of our 2015 Stock Incentive Plan. | Management | For | For |
| 4. | To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the current fiscal year. | Management | For | For |
| 5a. | To elect one Class III Director for a term to expire at our 2021 annual meeting of stockholders or until his successor is duly elected and qualified: Joseph Truitt | Management | For | For |

ADAMAS PHARMACEUTICALS, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 00548A106 | Meeting Type | Annual |
| Ticker Symbol | ADMS | Meeting Date | 06-Jun-2018 |
| Record Date | 09-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---|------------------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 | William W. Ericson | For | For |
| | 2 | Martha J. Demski | For | For |
| | 3 | Ivan Lieberburg MD PhD | For | For |
| 2. | To ratify the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2018. | Management | For | For |

ADAPT IMMUNE THERAPEUTICS PLC

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 00653A107 | Meeting Type | Annual |
| Ticker Symbol | ADAP | Meeting Date | 20-Jun-2018 |
| Record Date | 03-May-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1. | To re-elect as a director, Lawrence Alleva, who retires by rotation in accordance with the Articles of Association. | Management | For | For |
| 2. | To re-elect as a director, David Mott, who retires by rotation in accordance with the Articles of Association. | Management | For | For |
| 3. | To re-elect as a director, Elliott Sigal, who retires by rotation in accordance with the Articles of Association. | Management | For | For |
| 4. | To re-appoint KPMG LLP as our U.K. statutory auditors under the U.K. Companies Act 2006, to hold office until the conclusion of the next general meeting of shareholders at which the U.K. statutory accounts and reports are presented. | Management | For | For |
| 5. | To authorize the Audit Committee to determine our U.K. statutory auditors remuneration for the fiscal year ending December 31, 2018. | Management | For | For |
| 6. | To receive the U.K. statutory annual accounts and reports for ...(Due to space limits, see proxy material for full proposal). | Management | For | For |
| 7. | To receive and approve our U.K. statutory directors remuneration report for the year ended December 31, 2017. | Management | For | For |
| 8. | To receive and approve our Directors Remuneration Policy, which, if approved, will take effect upon conclusion of the Annual General Meeting. | Management | For | For |

AFFIMED N.V

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | N01045108 | Meeting Type | Annual |
| Ticker Symbol | AFMD | Meeting Date | 19-Jun-2018 |
| Record Date | 22-May-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|-------------|---|------------------------|-------------|-----------------------------------|
| 5 | Discussion of the 2017 Statutory Annual Report and proposal to adopt the financial statements for the financial year 2017, as prepared in accordance with Dutch law | Management | For | For |
| 7 | Amendment of the Remuneration Policy for the Supervisory Board (the SB Remuneration Policy) | Management | For | For |
| 8 | Discharge of the managing directors for their management during the financial year 2017 | Management | For | For |
| 9 | Discharge of the supervisory directors for their supervision during the financial year 2017 | Management | For | For |
| 10a | Appointment of: Dr. Mathieu Simon as a supervisory director | Management | For | For |
| 10b | Reappointment of: Dr. Ulrich M. Grau as a supervisory director | Management | For | For |
| 11 | Appointment of the auditor for the financial year 2018 | Management | For | For |
| 12 | Amendment of the articles of association | Management | For | For |
| 13 | Authorization to acquire shares | Management | For | For |

AGIOS PHARMACEUTICALS, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 00847X104 | Meeting Type | Annual |
| Ticker Symbol | AGIO | Meeting Date | 31-May-2018 |
| Record Date | 10-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 | Kaye Foster | For | For |
| | 2 | Maykin Ho, Ph.D. | For | For |
| | 3 | John M. Maraganore, PhD | For | For |
| 2. | To vote, on an advisory basis, to approve named executive officer compensation. | Management | For | For |
| 3. | To ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management | For | For |

AKEBIA THERAPEUTICS, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 00972D105 | Meeting Type | Annual |
| Ticker Symbol | AKBA | Meeting Date | 14-Jun-2018 |
| Record Date | 20-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---|-----------------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 | Michael D. Clayman | For | For |
| | 2 | Duane Nash | For | For |
| | 3 | Ronald C. Renaud, Jr. | For | For |
| | 4 | John P. Butler | For | For |
| | 5 | Muneer A. Satter | For | For |
| | 6 | Michael S. Wyzga | For | For |
| 2. | Ratification of the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management | For | For |

ALBIREO PHARMA INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 01345P106 | Meeting Type | Annual |
| Ticker Symbol | ALBO | Meeting Date | 08-Jun-2018 |
| Record Date | 18-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|----------|-------------|------|------------------------|
| 1. | DIRECTOR | Management | | |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| | | | | |
|----|---|------------|-----|-----|
| 1 | Ronald H.W. Cooper | | For | For |
| 2 | Anne Klibanski, M.D. | | For | For |
| 3 | Stephanie S. Okey, M.S. | | For | For |
| 2. | To approve the Albireo Pharma, Inc. 2018 Equity Incentive Plan. | Management | For | For |
| 3. | To approve the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan. | Management | For | For |
| 4. | To ratify the appointment of Ernst & Young LLP as Albireo's independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management | For | For |

ALDER BIOPHARMACEUTICALS, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 014339105 | Meeting Type | Annual |
| Ticker Symbol | ALDR | Meeting Date | 23-May-2018 |
| Record Date | 20-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 Paul B. Cleveland | | For | For |
| | 2 Stephen M. Dow | | For | For |
| | 3 A. Bruce Montgomery | | For | For |
| 2. | To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the accompanying proxy statement. | Management | For | For |
| 3. | To ratify the selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2018. | Management | For | For |

ALEXION PHARMACEUTICALS, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 015351109 | Meeting Type | Annual |
| Ticker Symbol | ALXN | Meeting Date | 08-May-2018 |
| Record Date | 12-Mar-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 Felix J. Baker | | For | For |
| | 2 David R. Brennan | | For | For |
| | 3 Christopher J. Coughlin | | For | For |
| | 4 Deborah Dunsire | | For | For |
| | 5 Paul A. Friedman | | For | For |
| | 6 Ludwig N. Hantson | | For | For |
| | 7 John T. Mollen | | For | For |
| | 8 Francois Nader | | For | For |
| | 9 Judith A. Reinsdorf | | For | For |
| | 10 Andreas Rummelt | | For | For |
| 2. | Ratification of appointment by the Board of Directors of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm. | Management | For | For |
| 3. | Approval of a non-binding advisory vote of the 2017 compensation paid to Alexion's named executive officers. | Management | For | For |
| 4. | To request the Board to require an independent Chairman. | Shareholder | For | Against |

ALKERMES PLC

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | G01767105 | Meeting Type | Annual |
| Ticker Symbol | ALKS | Meeting Date | 23-May-2018 |
| Record Date | 23-Mar-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|-------------|---|------------------------|-------------|-----------------------------------|
| 1a. | Election of Director: Floyd E. Bloom, M.D. | Management | For | For |
| 1b. | Election of Director: Nancy L. Snyderman, M.D. | Management | For | For |
| 1c. | Election of Director: Nancy Wysenski | Management | For | For |
| 2. | To approve, on an advisory basis, the compensation of the Company's named executive officers. | Management | For | For |
| 3. | To hold a non-binding, advisory vote, on the frequency of future advisory votes on the compensation paid to the Company's named executive officers. | Management | 1 Year | For |
| 4. | To ratify, on a non-binding, advisory basis, the appointment of PricewaterhouseCoopers LLP as the independent auditor and accounting firm of the Company and to authorize, in a binding vote, the Audit and Risk Committee of the Board of Directors to set the independent auditor and accounting firm's remuneration. | Management | For | For |
| 5. | To approve the Alkermes plc 2018 Stock Option and Incentive plan. | Management | For | For |

ALLIQUA BIOMEDICAL, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 019621200 | Meeting Type | Special |
| Ticker Symbol | ALQA | Meeting Date | 13-Sep-2017 |
| Record Date | 26-Jul-2017 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|-------------|--|--------------------|-------------|-------------------------------|
| 1. | To ratify the filing and effectiveness of the certificate of amendment to our amended and restated certificate of incorporation filed with the secretary of state of the state of delaware on may 6, 2016 and the increase in the number of shares of authorized common stock effected thereby. | Management | For | For |
| 2. | To approve the proposal to authorize the company s board of directors, in its discretion but prior to the annual meeting of the company s stockholders in 2018, to amend the company s certificate of incorporation to effect a reverse stock split of the company s common stock, at a ratio in the range of ...(due to space limits, see proxy statement for full proposal). | Management | For | For |
| 3. | To approve an adjournment of the special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of any of the foregoing proposals. | Management | For | For |

ALLIQUA BIOMEDICAL, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 019621309 | Meeting Type | Special |
| Ticker Symbol | ALQA | Meeting Date | 27-Apr-2018 |
| Record Date | 23-Mar-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|-------------|---|--------------------|-------------|-------------------------------|
| 1. | A proposal to approve the Asset Purchase Agreement, the Asset Sale Transaction and the other transactions contemplated by the Asset Purchase Agreement (the Asset Sale Proposal). | Management | For | For |
| 2. | A proposal to approve, on an advisory, non-binding basis, certain compensation that has, will or may be paid or become payable to the Company s named executive officers in connection with the asset sale (the Advisory Proposal). | Management | For | For |
| 3. | A proposal to adjourn or postpone the Special Meeting of stockholders, if necessary or appropriate, for the purpose of soliciting additional votes for the approval of the Asset Sale Proposal (the Adjournment Proposal). | Management | For | For |

ALLIQUA BIOMEDICAL, INC.

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

Security
Ticker Symbol
Record Date

019621309
 ALQA
 03-May-2018

Meeting Type
Meeting Date

Annual
 26-Jun-2018

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|---------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 | David Johnson | For | For |
| | 2 | Joseph Leone | For | For |
| | 3 | Gary Restani | For | For |
| | 4 | Jeffrey Sklar | For | For |
| | 5 | Mark Wagner | For | For |
| 2. | Ratification of the appointment of Marcum LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management | For | For |

ALNYLAM PHARMACEUTICALS, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 02043Q107 | Meeting Type | Annual |
| Ticker Symbol | ALNY | Meeting Date | 10-May-2018 |
| Record Date | 15-Mar-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|-------------|--|--------------------|-------------|-------------------------------|
| 1a. | Election of Class II Director: Dennis A. Ausiello, M.D. | Management | For | For |
| 1b. | Election of Class II Director: John K. Clarke | Management | For | For |
| 1c. | Election of Class II Director: Marsha H. Fanucci | Management | For | For |
| 1d. | Election of Class II Director: David E.I. Pyott | Management | For | For |
| 2. | To approve the 2018 Stock Incentive Plan. | Management | For | For |
| 3. | To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers. | Management | For | For |
| 4. | To ratify the appointment of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as Alnylam's independent auditors for the fiscal year ending December 31, 2018. | Management | For | For |

AMARIN CORPORATION PLC

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 023111206 | Meeting Type | Annual |
| Ticker Symbol | AMRN | Meeting Date | 14-May-2018 |
| Record Date | 18-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|-------------|--|--------------------|-------------|-------------------------------|
| 1. | To re-elect Mr. John F. Thero as a director. | Management | For | For |
| 2. | To re-elect Mr. Patrick J. O. Sullivan as a director. | Management | For | For |
| 3. | To hold an advisory (non-binding) vote to approve the compensation of the Company's named executive officers as described in full in the accompanying Proxy Statement. | Management | For | For |
| 4. | To appoint Ernst & Young LLP as auditors of the Company to hold office until the conclusion of the next general meeting at which accounts are laid before the Company and to authorize the Audit Committee of the Board of Directors of the Company to fix the auditors remuneration as described in the accompanying Proxy Statement. | Management | For | For |

AMGEN INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 031162100 | Meeting Type | Annual |
| Ticker Symbol | AMGN | Meeting Date | 22-May-2018 |
| Record Date | 23-Mar-2018 | | |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---|-------------|---------|------------------------|
| 1a. | Election of Director: Dr. Wanda M. Austin | Management | For | For |
| 1b. | Election of Director: Mr. Robert A. Bradway | Management | For | For |
| 1c. | Election of Director: Dr. Brian J. Druker | Management | For | For |
| 1d. | Election of Director: Mr. Robert A. Eckert | Management | For | For |
| 1e. | Election of Director: Mr. Greg C. Garland | Management | For | For |
| 1f. | Election of Director: Mr. Fred Hassan | Management | For | For |
| 1g. | Election of Director: Dr. Rebecca M. Henderson | Management | For | For |
| 1h. | Election of Director: Mr. Frank C. Herringer | Management | For | For |
| 1i. | Election of Director: Mr. Charles M. Holley, Jr. | Management | For | For |
| 1j. | Election of Director: Dr. Tyler Jacks | Management | For | For |
| 1k. | Election of Director: Ms. Ellen J. Kullman | Management | For | For |
| 1l. | Election of Director: Dr. Ronald D. Sugar | Management | For | For |
| 1m. | Election of Director: Dr. R. Sanders Williams | Management | For | For |
| 2. | Advisory vote to approve our executive compensation. | Management | For | For |
| 3. | To ratify the selection of Ernst & Young LLP as our independent registered public accountants for the fiscal year ending December 31, 2018. | Management | For | For |
| 4. | Stockholder proposal for an annual report on the extent to which risks related to public concern over drug pricing strategies are integrated into our executive incentive compensation. | Shareholder | Against | For |

AMICUS THERAPEUTICS, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 03152W109 | Meeting Type | Annual |
| Ticker Symbol | FOLD | Meeting Date | 07-Jun-2018 |
| Record Date | 16-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---|-----------------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 | Donald J. Hayden, Jr. | For | For |
| | 2 | Craig Wheeler | For | For |
| 2. | Proposal to approve an amendment to our Restated Certificate of Incorporation to increase the number of shares of common stock, par value \$0.01 per share, that we are authorized to issue from 250,000,000 to 500,000,000 | Management | For | For |
| 3. | Approval of the Amended and Restated 2007 Equity Incentive Plan to add 5,000,000 shares to the equity pool | Management | For | For |
| 4. | Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018 | Management | For | For |
| 5. | Approval, on an advisory basis, the Company's executive compensation | Management | For | For |

AMPHIVENA THERAPEUTICS, INC

| | | | |
|----------------------|-----|---------------------|-----------------|
| Security | N/A | Meeting Type | Written Consent |
| Ticker Symbol | N/A | Meeting Date | 20-Dec-2017 |
| Record Date | N/A | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1. | Approval of Amended and Restated Certificate of Incorporation | Management | For | For |
| 2. | Approval of Bridge Loan and Waiver of Right of First Offer | Management | For | For |
| 3. | Omnibus Resolutions | Management | For | For |

ARCA BIOPHARMA, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 00211Y407 | Meeting Type | Annual |
| Ticker Symbol | ABIO | Meeting Date | 31-May-2018 |
| Record Date | 02-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|----------|-------------|------|------------------------|
| 1. | DIRECTOR | Management | | |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| | | | | |
|----|--|------------|-----|-----|
| 1 | Raymond L. Woosley | | For | For |
| 2 | Daniel J. Mitchell | | For | For |
| 2. | To ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management | For | For |

ARDELYX, INC

Security 039697107 **Meeting Type** Annual
Ticker Symbol ARDX **Meeting Date** 13-Jun-2018
Record Date 20-Apr-2018

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---|------------------------|------|------------------------|
| 1. | DIRECTOR | | | |
| | 1 | William Bertrand, Jr. | For | For |
| | 2 | Annalisa Jenkins | For | For |
| | 3 | Jan M. Lundberg, Ph.D. | For | For |
| 2. | To ratify the selection, by the Audit Committee of our Board of Directors, of Ernst & Young, LLP as the independent registered public accounting firm of the Company for the fiscal year ended December 31, 2018. | Management | For | For |

ARENA PHARMACEUTICALS, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 040047607 | Meeting Type | Annual |
| Ticker Symbol | ARNA | Meeting Date | 13-Jun-2018 |
| Record Date | 24-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---|----------------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 | Jayson Dallas, M.D. | For | For |
| | 2 | Oliver Fetzer, Ph.D. | For | For |
| | 3 | Jennifer Jarrett | For | For |
| | 4 | Amit D. Munshi | For | For |
| | 5 | Garry A. Neil, M.D. | For | For |
| | 6 | Tina S. Nova, Ph.D. | For | For |
| | 7 | Randall E. Woods | For | For |
| 2. | To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying this notice. | Management | For | For |
| 3. | To approve the amendment and restatement of the Arena Pharmaceuticals, Inc., 2017 Long-Term Incentive Plan to, among other things, increase the number of shares authorized for issuance under the 2017 Long-Term Incentive Plan. | Management | For | For |
| 4. | To ratify the appointment of KPMG LLP, an independent registered public accounting firm, as our independent auditors for the fiscal year ending December 31, 2018. | Management | For | For |

ARGENX SE

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 04016X101 | Meeting Type | Special |
| Ticker Symbol | ARGX | Meeting Date | 07-Nov-2017 |
| Record Date | 10-Oct-2017 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1. | Amendment of the remuneration policy | Management | For | For |
| 2. | authorization of the board of directors to issue shares in the share capital of the company up to a maximum of 20% of the outstanding capital at the date of the general meeting, for a period of 18 months from the general meeting, in addition to the authorization to issue shares pursuant to the exercise of options | Management | For | For |
| 3. | Authorization of the board of directors to, insofar necessary, limit or exclude pre-emptive rights regarding an issuance of new shares for a period of 18 months from the general meeting | Management | For | For |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

ARGENX SE

| | | | |
|---|----------------------------------|----------------------------------|-----------------------|
| Security Ticker Symbol Record Date | 04016X101 ARGX 10-Apr-2018 | Meeting Type Meeting Date | Annual 08-May-2018 |
|---|----------------------------------|----------------------------------|-----------------------|

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 4b. | Adoption of the 2017 annual accounts | Management | For | For |
| 4d. | Allocation of losses of the Company in the financial year 2017 to the retained earnings of the Company | Management | For | For |
| 4e. | Proposal to release the members of the board of directors ...(due to space limits, see proxy material for full proposal). | Management | For | For |
| 5a. | Appointment of James Michael Daly as non-executive director to the board of directors of the Company | Management | For | For |
| 5b. | Re-appointment of Tim Van Hauwermeiren as executive director to the board of directors of the Company | Management | For | For |
| 5c. | Re-appointment of David L. Lacey as non-executive director to the board of directors of the Company | Management | For | For |
| 5d. | Re-appointment of Peter K.M. Verhaeghe as non-executive director to the board of directors of the Company | Management | For | For |
| 5e. | Re-appointment of Werner Lanthaler as non-executive director to the board of directors of the Company | Management | For | For |
| 6. | Authorization of the board of directors to grant options ...(due to space limits, see proxy material for full proposal). | Management | For | For |
| 7. | Authorization of the board of directors to issue shares in the ...(due to space limits, see proxy material for full proposal). | Management | For | For |
| 8. | Authorization of the board of directors to limit or exclude ...(due to space limits, see proxy material for full proposal). | Management | For | For |
| 9. | Appointment of Deloitte Accountants B.V. for the 2018 financial year | Management | For | For |

ASCENDIS PHARMA A S

| | | | |
|---|----------------------------------|----------------------------------|-----------------------|
| Security Ticker Symbol Record Date | 04351P101 ASND 19-Apr-2018 | Meeting Type Meeting Date | Annual 29-May-2018 |
|---|----------------------------------|----------------------------------|-----------------------|

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1. | Election of Chairman of the Meeting | Management | For | For |
| 2. | Report on the Company's Activities during the Past Year | Management | For | For |
| 3. | Presentation of Audited Annual Report with Auditor's Statement for Approval and Discharge of the Board of Directors and Management | Management | For | For |
| 4. | Resolution on Application of Profits or Covering of Losses as per the Adopted Annual Report | Management | For | For |
| 5a. | Election of Board Member: Albert Cha (Class II) | Management | For | For |
| 5b. | Election of Board Member: Birgitte Volck (Class II) | Management | For | For |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| | | | | |
|-----|---|------------|-----|-----|
| 5c. | Election of Board Member: Martin Olin (Class II) | Management | For | For |
| 6. | Election of State-authorized Public Auditor | Management | For | For |
| 7. | Any proposals from the Board of Directors and/or Shareholders: The Board of Directors proposes to renew the authorisation to the Board of Directors to issue warrants. Please refer to the Notice for additional information. | Management | For | For |

AURIS MEDICAL HOLDING AG

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | H03579101 | Meeting Type | Annual |
| Ticker Symbol | EARS | Meeting Date | 12-Mar-2018 |
| Record Date | 09-Feb-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1. | Approval of the merger between Auris Medical Holding AG (as transferring entity) and Auris Medical NewCo Holding AG (as surviving entity) according to the terms and conditions set forth by the merger agreement dated 9 February 2018 and based on the interim balance sheet of Auris Medical Holding AG as of 30 September 2017. German Version: Genehmigung der Fusion zwischen der Auris Medical Holding AG (als ubertragende Gesellschaft) und der Auris ... (due to space limits, see proxy statement for full proposal). | Management | For | For |
| 2. | Discharge of liability for the members of the Board of Directors and the Persons entrusted with the Company's Management. German Version: Entlastung der Mitglieder des Verwaltungsrats und der mit der Geschäftsführung der Gesellschaft betrauten Personen. | Management | For | For |
| 3.1 | Approval of the Compensation of the Board of Directors. German Version: Genehmigung der Vergütung des Verwaltungsrats. | Management | For | For |
| 3.2 | Approval of the Compensation of the members of the Executive Management Committee for the 2019 financial year. German Version: Genehmigung der Vergütung der Geschäftsleitung für das Geschäftsjahr 2019. | Management | For | For |
| 4.1 | Re-election of Thomas Meyer as member and as Chairman of the Board of Directors. German Version: Wiederwahl von Thomas Meyer als Mitglied und als Präsident des Verwaltungsrats. | Management | For | For |
| 4.2 | Re-election of Armando Anido as member of the Board of Directors. German Version: Wiederwahl von Armando Anido als Mitglied des Verwaltungsrats. | Management | For | For |
| 4.3 | Re-election of Mats Peter Blom as member of the Board of Directors. German Version: Wiederwahl von Mats Peter Blom als Mitglied des Verwaltungsrats. | Management | For | For |
| 4.4 | Re-election of Calvin W. Roberts as member of the Board of Directors. German Version: Wiederwahl von Calvin W. Roberts als Mitglied des Verwaltungsrats. | Management | For | For |
| 4.5 | Election of Alain Munoz as member of the Board of Directors. German Version: Wahl von Alain Munoz als Mitglied des Verwaltungsrats. | Management | For | For |
| 5.1 | Re-election of Armando Anido as member of the Compensation Committee. German Version: Wiederwahl von Armando Anido als Mitglied des Vergütungsausschusses. | Management | For | For |
| 5.2 | Election of Alain Munoz as member of the Compensation Committee. German Version: Wahl von Alain Munoz als Mitglied des Vergütungsausschusses. | Management | For | For |
| 6. | Re-election of Deloitte AG as Auditors. German Version: Wiederwahl von Deloitte AG als Revisionsstelle. | Management | For | For |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| | | | | |
|----|--|------------|-----|-----|
| 7. | Re-election of the Independent Proxy. German Version: Wiederwahl des unabhängigen Stimmrechtsvertreters. | Management | For | For |
| 8. | General instruction on new proposals of the Board of Directors. German Version: Allgemeine Weisungen zu nicht angekündigten Anträgen / Verhandlungsgegenständen. | Management | For | For |

AVADEL PHARMACEUTICALS PLC

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 05337M104 | Meeting Type | Annual |
| Ticker Symbol | AVDL | Meeting Date | 18-Jul-2018 |
| Record Date | 15-May-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1a. | Election of Director: Craig R. Stapleton | Management | For | For |
| 1b. | Election of Director: Michael S. Anderson | Management | For | For |
| 1c. | Election of Director: Peter Thornton | Management | For | For |
| 1d. | Election of Director: Geoffrey M. Glass | Management | For | For |
| 1e. | Election of Director: Linda S. Palczuk | Management | For | For |
| 2. | To ratify, in a non-binding vote, the appointment of Deloitte & Touche LLP as the Company's independent registered public auditor and accounting firm for the fiscal year ending December 31, 2018 and to authorize, in a binding vote, the Audit Committee of the Board to set the independent registered public auditor and accounting firm remuneration. | Management | For | For |
| 3. | To approve, on a non-binding advisory basis, the compensation of the named executive officers of the Company. | Management | For | For |
| 4. | To authorize the price range at which the Company can re-allot ordinary shares that it holds as treasury shares under Irish law. | Management | For | For |

BEIGENE LTD

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 07725L102 | Meeting Type | Annual |
| Ticker Symbol | BGNE | Meeting Date | 06-Jun-2018 |
| Record Date | 20-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1. | THAT Donald W. Glazer be and is hereby re-elected to serve as a Class II director of the Company until the 2021 annual general ... (due to space limits, see proxy material for full proposal). | Management | For | For |
| 2. | THAT Michael Goller be and is hereby re-elected to serve as a ... (due to space limits, see proxy material for full proposal). | Management | For | For |
| 3. | THAT Thomas Malley be and is hereby re-elected to serve as a Class II director of the Company until the 2021 annual general meeting of the shareholders of the Company and until his successor is duly elected and qualified, subject to his earlier resignation or removal. | Management | For | For |
| 4. | THAT the BeiGene, Ltd. 2018 Employee Share Purchase Plan be and is hereby approved and adopted. | Management | For | For |
| 5. | | Management | For | For |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| | | | | |
|----|--|------------|--------|-----|
| | THAT the appointment of Ernst & Young Hua Ming LLP as the Company's independent registered public accounting firm for the ... (due to space limits, see proxy material for full proposal). | | | |
| 6. | THAT, on a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement for the Meeting, be and is hereby approved. | Management | For | For |
| 7. | THAT, on a non-binding, advisory basis, future advisory votes on the compensation of the Company's named executive officers will be held at the frequency hereby approved. | Management | 1 Year | For |

BELLICUM PHARMACEUTICALS INC

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 079481107 | Meeting Type | Annual |
| Ticker Symbol | BLCM | Meeting Date | 14-Jun-2018 |
| Record Date | 17-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 | Frank B. McGuyer | For | For |
| | 2 | Jon P. Stonehouse | For | For |
| | 3 | Stephen R. Davis | For | For |
| 2. | Ratification of selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2018. | Management | For | For |

BIOCLIN THERAPEUTICS, INC.

| | | | |
|----------------------|-----|---------------------|-----------------|
| Security | N/A | Meeting Type | Written Consent |
| Ticker Symbol | N/A | Meeting Date | 27-Sep-2017 |
| Record Date | N/A | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--------------------------------|-------------|------|------------------------|
| 1. | Election of Director | Management | For | For |
| 2. | General Authorizing Resolution | Management | For | For |

BIOCLIN THERAPEUTICS, INC.

| | | | |
|----------------------|-----|---------------------|-----------------|
| Security | N/A | Meeting Type | Written Consent |
| Ticker Symbol | N/A | Meeting Date | 24-Apr-2018 |
| Record Date | N/A | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1. | Amendment and Restatement of Restated Certificate of Incorporation | Management | For | For |
| 2. | Series B Preferred Stock Financing | Management | For | For |
| 3. | Waiver of Preemptive Rights | Management | For | For |
| 4. | Notice of Interested Party Transactions | Management | For | For |
| 5. | Amendment of 2013 Stock and Option Grant Plan | Management | For | For |
| 6. | General Authorizing Resolution | Management | For | For |

BIOCLIN THERAPEUTICS, INC.

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| | | | |
|----------------------|-----|---------------------|-----------------|
| Security | N/A | Meeting Type | Written Consent |
| Ticker Symbol | N/A | Meeting Date | 21-May-2018 |
| Record Date | N/A | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|-------------|--------------------------------|------------------------|-------------|-----------------------------------|
| 1. | Election of Director | Management | For | For |
| 2. | General Authorizing Resolution | Management | For | For |

BIOGEN INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 09062X103 | Meeting Type | Annual |
| Ticker Symbol | BIIB | Meeting Date | 12-Jun-2018 |
| Record Date | 17-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|-------------|---|--------------------|-------------|-------------------------------|
| 1a. | Election of Director: Alexander J. Denner | Management | For | For |
| 1b. | Election of Director: Caroline D. Dorsa | Management | For | For |
| 1c. | Election of Director: Nancy L. Leaming | Management | For | For |
| 1d. | Election of Director: Richard C. Mulligan | Management | For | For |
| 1e. | Election of Director: Robert W. Pangia | Management | For | For |
| 1f. | Election of Director: Stelios Papadopoulos | Management | For | For |
| 1g. | Election of Director: Brian S. Posner | Management | For | For |
| 1h. | Election of Director: Eric K. Rowinsky | Management | For | For |
| 1i. | Election of Director: Lynn Schenk | Management | For | For |
| 1j. | Election of Director: Stephen A. Sherwin | Management | For | For |
| 1k. | Election of Director: Michel Vounatsos | Management | For | For |
| 2. | To ratify the selection of PricewaterhouseCoopers LLP as Biogen Inc. s independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management | For | For |
| 3. | Say on Pay - To approve an advisory vote on executive compensation. | Management | For | For |
| 4. | Stockholder proposal requesting certain proxy access bylaw amendments. | Shareholder | Against | For |
| 5. | Stockholder proposal requesting a report on the extent to which risks related to public concern over drug pricing strategies are integrated into incentive compensation arrangements. | Shareholder | Against | For |

BIOHAVEN PHARMACEUTICAL HLDG CO LTD

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | G11196105 | Meeting Type | Annual |
| Ticker Symbol | BHVN | Meeting Date | 01-May-2018 |
| Record Date | 26-Mar-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|-------------|---|--------------------|-------------|-------------------------------|
| 1A. | Election of Director: Dr. Eric I. Aguiar | Management | For | For |
| 1B. | Election of Director: Dr. Albert Cha | Management | For | For |
| 1C. | Election of Director: Ms. Julia P. Gregory | Management | For | For |
| 2. | Ratification of appointment of PricewaterhouseCoopers LLP as independent auditors for fiscal year 2018. | Management | For | For |

BIOMARIN PHARMACEUTICAL INC.

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 09061G101 | Meeting Type | Annual |
| Ticker Symbol | BMRN | Meeting Date | 05-Jun-2018 |
| Record Date | 09-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|-------------|---|-----------------------|-------------|-------------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 | Jean-Jacques Bienaime | For | For |
| | 2 | Willard Dere | For | For |
| | 3 | Michael Grey | For | For |
| | 4 | Elaine J. Heron | For | For |
| | 5 | Robert J. Hombach | For | For |
| | 6 | V. Bryan Lawlis | For | For |
| | 7 | Alan J. Lewis | For | For |
| | 8 | Richard A. Meier | For | For |
| | 9 | David E.I. Pyott | For | For |
| | 10 | Dennis J. Slamon | For | For |
| 2. | To ratify the selection of KPMG LLP as the independent registered public accounting firm for BioMarin for the fiscal year ending December 31, 2018. | Management | For | For |
| 3. | To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement. | Management | For | For |

BLUEBIRD BIO, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 09609G100 | Meeting Type | Annual |
| Ticker Symbol | BLUE | Meeting Date | 20-Jun-2018 |
| Record Date | 23-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|-------------|---|--------------------|-------------|-------------------------------|
| 1a. | Election of Class II Director: John O. Agwunobi, M.D. | Management | For | For |
| 1b. | Election of Class II Director: Mary Lynne Hedley, Ph.D | Management | For | For |
| 1c. | Election of Class II Director: Daniel S. Lynch | Management | For | For |
| 2. | To hold a non-binding advisory vote on the compensation paid to the Company's named executive officers. | Management | For | For |
| 3. | To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management | For | For |

BLUEPRINT MEDICINES CORPORATION

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 09627Y109 | Meeting Type | Annual |
| Ticker Symbol | BPMC | Meeting Date | 20-Jun-2018 |
| Record Date | 23-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|-------------|--|--------------------|-------------|-------------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 Daniel S. Lynch | | For | For |
| | 2 George D. Demetri, M.D. | | For | For |
| | 3 Lynn Seely, M.D. | | For | For |
| 2. | To approve an advisory vote on named executive officer compensation. | Management | For | For |
| 3. | To hold an advisory vote on the frequency of future advisory votes on named executive officer compensation. | Management | 1 Year | For |
| 4. | Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ended December 31, 2018. | Management | For | For |

CELGENE CORPORATION

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 151020104 | Meeting Type | Annual |
| Ticker Symbol | CELG | Meeting Date | 13-Jun-2018 |
| Record Date | 19-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------|---------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 Mark J. Alles | | For | For |
| | 2 R W Barker, D.Phil, OBE | | For | For |
| | 3 Hans E. Bishop | | For | For |
| | 4 Michael W. Bonney | | For | For |
| | 5 Michael D. Casey | | For | For |
| | 6 Carrie S. Cox | | For | For |
| | 7 Michael A. Friedman, MD | | For | For |
| | 8 Julia A. Haller, M.D. | | For | For |
| | 9 P. A. Hemingway Hall | | For | For |
| | 10 James J. Loughlin | | For | For |
| | 11 Ernest Mario, Ph.D. | | For | For |
| | 12 John H. Weiland | | For | For |
| 2. | Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management | For | For |
| 3. | Approval, by non-binding vote, of executive compensation of the Company's named executive officers. | Management | For | For |
| 4. | Advisory vote on stockholder proposal to request the Company's Board of Directors to amend the Company's proxy access by-law provision to eliminate the limit on the number of stockholders that can aggregate their shares to achieve the holding requirement for nomination of directors, described in more detail in the proxy statement. | Shareholder | Against | For |
| 5. | Advisory vote on stockholder proposal to request the Company's Board of Directors to adopt a policy and amend the Company's governing documents to require that the Chairman of the Board be an independent member, described in more detail in the proxy statement. | Shareholder | For | Against |

CELLECTIS S.A.

| | | | |
|---|----------------------------------|----------------------------------|-----------------------|
| Security Ticker Symbol Record Date | 15117K103 CLLS 11-Jun-2018 | Meeting Type Meeting Date | Annual 26-Jun-2018 |
|---|----------------------------------|----------------------------------|-----------------------|

| Item | Proposal | Proposed by | Vote | For/Against Management |
|-------------|---|--------------------|-------------|-------------------------------|
| 1. | Approval of the financial statements for the financial year ended December 31, 2017 | Management | For | For |
| 2. | Approval of the consolidated financial statements for the financial year ended December 31, 2017 | Management | For | For |
| 3. | Allocation of income for the financial year ended December 31, 2017 | Management | For | For |
| 4. | Approval of the agreements referred to in articles L. 225-38 and the following sections of the French commercial code | Management | For | For |
| 5. | Setting the amount of the attendance fees to be granted to the non-executive directors | Management | For | For |
| 6. | Renewal of the term of office of director of Mr. Andre Choulika | Management | For | For |
| 7. | Renewal of the term of office of director of Mr. David Sourdive | Management | For | For |
| 8. | Renewal of the term of office of director of Mr. Alain-Paul Godard, independent director according to the rules of the U.S. Securities Exchange Act of 1934 (the Exchange Act) and Nasdaq Stock Market | Management | For | For |
| 9. | Renewal of the term of office of J.M.H. Conseil, as Company's Statutory Auditors | Management | For | For |
| 10. | Renewal of the term of office of Ernst & Young et Autres, as Company's Statutory Auditors | Management | For | For |
| 11. | Approval of 2017 Stock Option Plan and payment for the stock options or stock purchase plan adopted by the Board of Directors on October 11, 2017 | Management | For | For |
| 12. | Authorization to be given to the Board of Directors to buy back Company shares | Management | For | For |
| 13. | Authorization to be given to the Board of Directors for the purpose of reducing the share capital through the cancellation of shares in the context of the authorization to buy back its own shares | Management | For | For |
| 14. | Delegation of authority to be granted to the Board of Directors for the purpose of increasing the share capital by issuing ordinary shares and/or any securities, with a waiver of the preferential subscription rights of the shareholders, in favor of a category of persons meeting specified characteristics | Management | For | For |
| 15. | Delegation of authority to be granted to the Board of Directors for the purpose of increasing the share capital through the issuance of ordinary shares or of any securities with a waiver of the preferential subscription rights of the shareholders, in favor of a category of persons ensuring the underwriting of the Company's equity securities that may arise as part of an equity line financing or bond financing | Management | For | For |
| 16. | Delegation of authority to be granted to the Board of Directors for the purpose of increasing the share capital | Management | For | For |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

immediately or in the future by issuing ordinary shares or any securities, while maintaining the preferential subscription rights of shareholders

| | | | | |
|-----|---|------------|-----|-----|
| 17. | Delegation of authority to be granted to the Board of Directors for the purpose of increasing the share capital through the issuance of ordinary shares and/or any securities, with waiver of the preferential subscription rights of the shareholders, through a public offering | Management | For | For |
| 18. | Delegation of authority to be granted to the Board of Directors for the purpose of increasing the share capital through the issuance of ordinary shares and/or of any securities, with waiver of the preferential subscription rights of the shareholders, through an offer to qualified investors or a restricted circle of investors within the meaning of paragraph II of article L. 411-2 of the French monetary and financial code | Management | For | For |
| 19. | Delegation granted to the Board of Directors to increase the number of securities to be issued in case of share capital increase with or without preferential subscription rights | Management | For | For |
| 20. | Overall limitations to the amount of issuances made under the 14th resolution, the 15th resolution, the 16th resolution, the 17th resolution, the 18th resolution, and the 19th resolution above | Management | For | For |
| 21. | Delegation of authority to be granted to the Board of Directors for the purpose of increasing the share capital by incorporation of premiums, reserves, profits or others | Management | For | For |
| 22. | Authorization to be given to the Board of Directors to grant options to subscribe or purchase Company's shares | Management | For | For |
| 23. | Authorization be given to the Board of Directors for the allocation of free shares existing and/or to be issued in the future | Management | For | For |
| 24. | Delegation of authority to be granted to the Board of Directors to issue warrants giving the right to subscribe ordinary shares of the Company - Cancellation of the preferential right of subscription to the benefit of a category of persons meeting specific characteristics | Management | For | For |
| 25. | Delegation of authority to be granted to the Board of Directors for the purpose of issuing warrants to subscribe to and/or acquire redeemable shares (BSAAR) or share subscription warrants - with a waiver of the preferential subscription rights in favor of the following category of beneficiaries: employees and corporate officers of the Company and its subsidiaries | Management | For | For |
| 26. | Authorization for the Board of Directors to freely allocate preferred shares of the Company to the employees and and/or the executive officers of the Company and its subsidiaries entailing the waiver by the shareholders of their preferential subscription rights | Management | For | For |
| 27. | Overall limitations to the amount of issues made under the 22nd resolution, the 23rd resolution, the 24th resolution, the 25th resolution and the 26th resolution above | Management | For | For |
| 28. | Removal of the obligation to submit certain decisions to the Board of Directors approval, as listed in Article 14.1.1. Section 4 of the bylaws | Management | For | For |
| 29. | Delegation to be granted to the Board of Directors for the purpose of an increase in the share capital whose subscription would be reserved to members of a company savings plan established pursuant to articles L. 3332-1 and following of the French labor code | Management | For | N/A |

CIDARA THERAPEUTICS, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 171757107 | Meeting Type | Annual |
| Ticker Symbol | CDTX | Meeting Date | 13-Jun-2018 |
| Record Date | 18-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---|-----------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 | Timothy Franson | For | For |
| | 2 | Chrysa Mineo | For | For |
| 2. | Ratification of the appointment of the company's independent registered public accounting firm for its fiscal year ending December 31, 2018 | Management | For | For |

CLOVIS ONCOLOGY, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 189464100 | Meeting Type | Annual |
| Ticker Symbol | CLVS | Meeting Date | 07-Jun-2018 |
| Record Date | 09-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------------------|--------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 | Patrick J. Mahaffy | For | For |
| | 2 | M. James Barrett, Ph.D. | For | For |
| | 3 | Thorlef Spickschen | For | For |
| 2. | Approval and ratification of our Non-Employee Director Compensation Policy. | Management | For | For |
| 3. | Approval of an advisory proposal on compensation of the Company's named executive officers, as disclosed in the attached proxy statement. | Management | For | For |
| 4. | Approval of an advisory proposal on the preferred frequency of the stockholder vote on the compensation of the Company's named executive officers. | Management | 1 Year | For |
| 5. | Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2018. | Management | For | For |

CRISPR THERAPEUTICS AG

| | | | |
|---|----------------------------------|----------------------------------|-----------------------|
| Security Ticker Symbol Record Date | H17182108 CRSP 02-Apr-2018 | Meeting Type Meeting Date | Annual 30-May-2018 |
|---|----------------------------------|----------------------------------|-----------------------|

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1. | The approval of the annual report, the consolidated financial statements and the statutory financial statements of the Company for the year ended December 31, 2017. | Management | For | For |
| 2. | The approval of the appropriation of financial results. | Management | For | For |
| 3. | The discharge of the members of the Board of Directors and Executive Committee. | Management | For | For |
| 4a. | Re-election of the member to the Board of Director: Rodger Novak, M.D. (as member and Chairman) | Management | For | For |
| 4b. | Election of the member to the Board of Director: Samarth Kulkarni, Ph.D. | Management | For | For |
| 4c. | Re-election of the member to the Board of Director: Bradley Bolzon, Ph.D. | Management | For | For |
| 4d. | Re-election of the member to the Board of Director: Ali Behbahani, M.D. | Management | For | For |
| 4e. | Re-election of the member to the Board of Director: Pablo Cagnoni, M.D. | Management | For | For |
| 4f. | Re-election of the member to the Board of Director: Kurt von Emster | Management | For | For |
| 4g. | Re-election of the member to the Board of Director: Simeon J. George, M.D. | Management | For | For |
| 4h. | Re-election of the member to the Board of Director: Thomas Woiwode, Ph.D. | Management | For | For |
| 5a. | Re-election of the member of the Compensation Committee: Thomas Woiwode, Ph.D. | Management | For | For |
| 5b. | Re-election of the member of the Compensation Committee: Pablo Cagnoni, M.D. | Management | For | For |
| 5c. | Re-election of the member of the Compensation Committee: Simeon J. George, M.D. | Management | For | For |
| 6a. | Binding vote on total non-performance-related compensation for members of the Board of Directors from the 2018 Annual General Meeting to the 2019 annual general meeting of shareholders. | Management | For | For |
| 6b. | Binding vote on equity for members of the Board of Directors from the 2018 Annual General Meeting to the 2019 annual general meeting of shareholders. | Management | For | For |
| 6c. | Binding vote on total non-performance-related compensation for members of the Executive Committee from July 1, 2018 to June 30, 2019. | Management | For | For |
| 6d. | Binding vote on total variable compensation for members of the Executive Committee for the current year ending December 31, 2018. | Management | For | For |
| 6e. | Binding vote on equity for members of the Executive Committee from the 2018 Annual General Meeting to the 2019 annual general meeting of shareholders. | Management | For | For |
| 7. | The approval of an increase in the Conditional Share Capital for Employee Benefit Plans. | Management | For | For |
| 8. | | Management | For | For |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| | | | | |
|-----|---|------------|-----|-----|
| | The approval of the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan. | | | |
| 9. | The approval of increasing the maximum number of authorized share capital and extending the date by which the Board of Directors may increase authorized share capital. | Management | For | For |
| 10. | The re-election of the independent voting rights representative. | Management | For | For |
| 11. | The re-election of the auditors. | Management | For | For |

CYMABAY THERAPEUTICS INC

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 23257D103 | Meeting Type | Annual |
| Ticker Symbol | CBAY | Meeting Date | 05-Jun-2018 |
| Record Date | 09-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 | Sujal A. Shah | For | For |
| | 2 | Robert F. Booth, Ph.D. | For | For |
| | 3 | Carl Goldfischer, M.D. | For | For |
| | 4 | Caroline Loewy | For | For |
| | 5 | Evan A. Stein, M.D. PhD | For | For |
| | 6 | Paul F. Truex | For | For |
| | 7 | Kurt von Emster | For | For |
| | 8 | Robert J. Weiland | For | For |
| | 9 | Robert J. Wills, Ph.D. | For | For |
| 2. | To approve the CymaBay Therapeutics, Inc. 2013 Equity Incentive Plan, as amended and restated, to, among other things, increase the aggregate number of shares of the company's common stock authorized for issuance under the plan by 1,500,000 shares. | Management | For | For |
| 3. | To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of CymaBay Therapeutics, Inc. for its fiscal year ending December 31, 2018. | Management | For | For |

CYTOKINETICS, INCORPORATED

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 23282W605 | Meeting Type | Annual |
| Ticker Symbol | CYTK | Meeting Date | 16-May-2018 |
| Record Date | 03-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---|-----------------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 | Robert I. Blum | For | For |
| | 2 | Robert M. Califf M.D. | For | For |
| | 3 | Sandford D. Smith | For | For |
| 2. | Ratification of selection of Ernst & Young LLP as the independent registered public accounting firm of Cytokinetics, Incorporated for the fiscal year ending December 31, 2018. | Management | For | For |
| 3. | Approval, on an advisory basis, of the compensation of the named executive officers. | Management | For | For |

CYTOMX THERAPEUTICS, INC.

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 23284F105 | Meeting Type | Annual |
| Ticker Symbol | CTMX | Meeting Date | 13-Jun-2018 |
| Record Date | 23-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|-------------|---|------------------------|-------------|-----------------------------------|
| 1a. | Election of Director: Charles S. Fuchs | Management | For | For |
| 1b. | Election of Director: Hoyoung Huh | Management | For | For |
| 2. | To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2018. | Management | For | For |

DERMIRA, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 24983L104 | Meeting Type | Annual |
| Ticker Symbol | DERM | Meeting Date | 12-Jun-2018 |
| Record Date | 16-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|-------------|--|--------------------|-------------|-------------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 Matthew K. Fust | | For | For |
| | 2 William R. Ringo | | For | For |
| | 3 Kathleen Sebelius | | For | For |
| 2. | Vote, on a non-binding advisory basis, on the compensation paid by us to our named executive officers for the year ended December 31, 2017. | Management | For | For |
| 3. | Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2018. | Management | For | For |
| 4. | Such other business as may properly come before the meeting or any adjournment thereof. | Management | Abstain | Against |

DYNAVAX TECHNOLOGIES CORPORATION

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 268158201 | Meeting Type | Special |
| Ticker Symbol | DVAX | Meeting Date | 31-Jul-2017 |
| Record Date | 30-Jun-2017 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|-------------|---|--------------------|-------------|-------------------------------|
| 1. | To approve an amendment to the company's sixth amended and restated certificate of incorporation, as amended, to increase the authorized number of shares of common stock from 69,500,000 to 139,000,000. | Management | For | For |
| 2. | To authorize an adjournment of the meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the proposal 1. | Management | For | For |

EDITAS MEDICINE INC

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 28106W103 | Meeting Type | Annual |
| Ticker Symbol | EDIT | Meeting Date | 15-Jun-2018 |
| Record Date | 18-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|-------------|-----------------|--------------------|-------------|-------------------------------|
| 1. | DIRECTOR | Management | | |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| | | | | |
|----|---|------------|-----|-----|
| 1 | Andrew Hirsch | | For | For |
| 2 | Boris Nikolic, M.D. | | For | For |
| 2. | Ratification of the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management | For | For |

EIGER BIOPHARMACEUTICALS,INC

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 28249U105 | Meeting Type | Annual |
| Ticker Symbol | EIGR | Meeting Date | 12-Jun-2018 |
| Record Date | 23-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---|-----------------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 | Thomas J. Dietz, Ph.D | For | For |
| | 2 | Eldon Mayer | For | For |
| 2. | To ratify the selection by the Audit Committee of our Board of Directors of KPMG LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2018. | Management | For | For |

ENDO INTERNATIONAL PLC

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | G30401106 | Meeting Type | Annual |
| Ticker Symbol | ENDP | Meeting Date | 07-Jun-2018 |
| Record Date | 13-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1a. | Election of Director: Roger H. Kimmel | Management | For | For |
| 1b. | Election of Director: Paul V. Campanelli | Management | For | For |
| 1c. | Election of Director: Shane M. Cooke | Management | For | For |
| 1d. | Election of Director: Nancy J. Hutson, Ph.D. | Management | For | For |
| 1e. | Election of Director: Michael Hyatt | Management | For | For |
| 1f. | Election of Director: Sharad S. Mansukani, M.D. | Management | For | For |
| 1g. | Election of Director: William P. Montague | Management | For | For |
| 1h. | Election of Director: Todd B. Sisitsky | Management | For | For |
| 2. | To approve the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2018 and to authorize the Board of Directors, acting through the Audit Committee, to determine the independent registered public accounting firm's remuneration. | Management | For | For |
| 3. | To approve, by advisory vote, named executive officer compensation. | Management | For | For |
| 4. | To approve the Endo International plc Amended and Restated 2015 Stock Incentive Plan. | Management | For | For |
| 5. | To renew the Board's existing authority to issue shares under Irish law. | Management | For | For |
| 6. | To renew the Board's existing authority to opt-out of statutory pre-emption rights under Irish law. | Management | For | For |

EPIZYME, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 29428V104 | Meeting Type | Annual |
| Ticker Symbol | EPZM | Meeting Date | 18-May-2018 |
| Record Date | 23-Mar-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 Kevin Conroy | | For | For |
| | 2 Carl Goldfischer, M.D. | | For | For |
| | 3 Beth Seidenberg, M.D. | | For | For |
| 2. | Ratification of the appointment of Ernst & Young LLP as Epizyme's independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management | For | For |

ESPERION THERAPEUTICS INC

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 29664W105 | Meeting Type | Annual |
| Ticker Symbol | ESPR | Meeting Date | 23-May-2018 |
| Record Date | 26-Mar-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|-------------|--|--------------------|-------------|-------------------------------|
| 1a. | Election of Class II Director: Jeffrey Berkowitz, J.D. | Management | For | For |
| 1b. | Election of Class II Director: Antonio M. Gotto Jr., M.D., D.Phil. | Management | For | For |
| 1c. | Election of Class II Director: Nicole Vitullo | Management | For | For |
| 2. | To approve the advisory resolution on the compensation of our named executive officers | Management | For | For |
| 3. | To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018 | Management | For | For |

EUTHYMICS BIOSCIENCE, INC.

| | | | |
|----------------------|-----|---------------------|-----------------|
| Security | N/A | Meeting Type | Written Consent |
| Ticker Symbol | N/A | Meeting Date | 11-Jul-2017 |
| Record Date | N/A | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|-------------|------------------|--------------------|-------------|-------------------------------|
| 1. | Bridge Financing | Management | For | For |

EUTHYMICS BIOSCIENCE, INC.

| | | | |
|----------------------|-----|---------------------|-----------------|
| Security | N/A | Meeting Type | Written Consent |
| Ticker Symbol | N/A | Meeting Date | 27-Sep-2017 |
| Record Date | N/A | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|-------------|----------------------|--------------------|-------------|-------------------------------|
| 1. | Sale and Dissolution | Management | For | For |
| 2. | Dissolution | Management | For | For |
| 3. | General | Management | For | For |

EXELIXIS, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 30161Q104 | Meeting Type | Annual |
| Ticker Symbol | EXEL | Meeting Date | 23-May-2018 |
| Record Date | 29-Mar-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|-------------|---|--------------------|-------------|-------------------------------|
| 1.1 | Election of Class I Director: Charles Cohen, Ph.D. | Management | For | For |
| 1.2 | Election of Class I Director: George Poste, DVM, Ph.D., FRS | Management | For | For |
| 1.3 | Election of Class I Director: Jack L. Wyszomierski | Management | For | For |
| 2. | To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as Exelixis independent registered public accounting firm for the fiscal year ending December 28, 2018. | Management | For | For |
| 3. | To approve, on an advisory basis, the compensation of Exelixis named executive officers, as disclosed in the accompanying Proxy Statement. | Management | For | For |

FIBROGEN, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 31572Q808 | Meeting Type | Annual |
| Ticker Symbol | FGEN | Meeting Date | 05-Jun-2018 |
| Record Date | 09-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|-------------|---|--------------------|-------------|-------------------------------|
| 1a. | Election of Class I Director: Thomas B. Neff | Management | For | For |
| 1b. | Election of Class I Director: Jeffrey W. Henderson | Management | For | For |
| 1c. | Election of Class I Director: James A. Schoeneck | Management | For | For |
| 2. | To approve, on an advisory basis, the compensation of FibroGen s named executive officers, as disclosed in the proxy statement. | Management | For | For |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| | | | | |
|----|--|------------|-----|-----|
| 3. | To ratify the selection of PricewaterhouseCoopers LLP by the Audit Committee of the Board of Directors as the independent registered public accounting firm of FibroGen for the year ending December 31, 2018. | Management | For | For |
|----|--|------------|-----|-----|

FOAMIX PHARMACEUTICALS LTD

| | | | |
|---|----------------------------------|----------------------------------|------------------------|
| Security Ticker Symbol Record Date | M46135105 FOMX 25-Oct-2017 | Meeting Type Meeting Date | Special 27-Nov-2017 |
|---|----------------------------------|----------------------------------|------------------------|

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------|---------|------------------------|
| 1. | (i) Pay mr. domzalski annual compensation of \$440,000 for his services as the chief executive officer of the company, effective as of July 1, 2017, (ii) approve mr. domzalski's cash bonus for the six month period commencing as of July 1, 2017 up to a maximum amount of \$132,000, subject to ...(due to space limits, see proxy statement for full proposal). | Management | For | For |
| 1A. | Do you have a personal interest in the approval of this proposal #1? mark for = yes or against = no. | Management | Against | N/A |
| 2. | Award mr. domzalski 327,720 options and 81,930 rsus under the company's 2015 Israeli share incentive plan and its 2015 U.S. addendum. | Management | For | For |
| 2A. | Do you have a personal interest in the approval of this proposal #2? mark for = yes or against = no. | Management | Against | N/A |

FOAMIX PHARMACEUTICALS LTD

| | | | |
|---|----------------------------------|----------------------------------|-----------------------|
| Security Ticker Symbol Record Date | M46135105 FOMX 10-Apr-2018 | Meeting Type Meeting Date | Annual 08-May-2018 |
|---|----------------------------------|----------------------------------|-----------------------|

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------|---------|------------------------|
| 1 | Appoint Kesselman & Kesselman (a member firm of PricewaterhouseCoopers International Limited, or PwC) an independent registered public accounting firm, as the Company's independent public accountants for the fiscal year ending December 31, 2018, and authorize the Board (or the Audit Committee, if such authority is delegated to it by the Board) to fix the remuneration of such independent public accountants in accordance with the volume and nature of their services. | Management | For | For |
| 2 | Ratify the election of Mr. David Domzalski as a director of the Company. | Management | For | For |
| 3 | Approve the annual equity incentive awards to the Company's non-executive directors, as set out under Proposal 3 in the Company's proxy statement. | Management | For | For |
| 4a | Approve the equity incentive grants to Mr. Domzalski for 2017, as set out under Proposal 4(a) in the Company's proxy statement. | Management | For | For |
| 4a1 | Please confirm you are a controlling shareholder/have a personal interest in the approval of Proposal 4(a)? If you vote FOR=YES or not at all your vote may not count for the Corresponding Proposal For= Yes, No=Against | Management | Against | N/A |
| 4b | Approve the terms of Mr. Domzalski's cash bonus and equity compensation for 2018, as set out under Proposal 4(b) of the Company's proxy statement. | Management | For | For |
| 4b1 | Please confirm you are a controlling shareholder/have a personal interest in the approval of Proposal 4(b)? If you vote FOR=YES or not at all your vote may not count for the Corresponding Proposal For= Yes, No=Against | Management | Against | N/A |
| 5a | Approve the 2016 equity conversion bonus for Dr. Tamarkin in respect of 2016, as set out under Proposal 5(a) of the Company's proxy statement | Management | For | For |
| 5a1 | Please confirm you are a controlling shareholder/have a personal interest in the approval of Proposal 5(a)? If you vote FOR=YES or not at all your vote may not count for the Corresponding Proposal For= Yes, No=Against | Management | Against | N/A |
| 5b | Approve Dr. Tamarkin's cash bonus in respect of the first half of 2017, as set out under Proposal 5(b) of the Company's proxy statement. | Management | For | For |
| 5b1 | Please confirm you are a controlling shareholder/have a personal interest in the approval of Proposal 5(b)? If you vote FOR=YES or not at all your vote may not count for the Corresponding Proposal For= Yes, No=Against | Management | Against | N/A |
| 6. | Approve the Company's Amended Compensation Policy, as set out under Proposal 6 of the Company's proxy statement. | Management | For | For |
| 6a | Please confirm you are a controlling shareholder/have a personal interest in the approval of Proposal 6? If you vote FOR=YES or not at all your vote may not count for the | Management | Against | N/A |

Corresponding Proposal For= Yes, No=Against

GALAPAGOS N V

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 36315X101 | Meeting Type | Annual |
| Ticker Symbol | GLPG | Meeting Date | 24-Apr-2018 |
| Record Date | 20-Mar-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|-------------|---|--------------------|-------------|-------------------------------|
| 2. | Acknowledgement and approval of the non-consolidated annual accounts of the Company for the financial year ended on 31 December 2017 and approval of the allocation of the annual result as proposed by the board of directors. | Management | For | N/A |
| 5. | Acknowledgement and approval of the remuneration report. | Management | For | N/A |
| 6. | Release from liability to be granted to the directors and the statutory auditor for the performance of their duties in the course of the financial year ended 31 December 2017. | Management | For | N/A |
| 7.1 | Re-appointment of Dr. Werner Cautreels as director of the Company. | Management | For | N/A |
| 7.2 | Re-appointment of Mr. Howard Rowe as director of the Company. | Management | For | N/A |
| 8. | Remuneration of directors. | Management | For | N/A |
| 9. | Offer of warrants. | Management | For | N/A |

GALAPAGOS N V

| | | | |
|---|-------------------------------------|----------------------------------|---------------------------------------|
| Security Ticker Symbol Record Date | B44170106 GLPG NA 10-Apr-2018 | Meeting Type Meeting Date | Annual General Meeting 24-Apr-2018 |
|---|-------------------------------------|----------------------------------|---------------------------------------|

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| CMMT | Market rules require disclosure of beneficial owner information for all voted-accounts. If an account has multiple beneficial owners, you will need to-provide the breakdown of each beneficial owner name, address and share-position to your client service representative. This information is required-in order for your vote to be lodged | Non-Voting | N/A | N/A |
| CMMT | Important market processing requirement: a beneficial owner signed power of- attorney (poa) may be required in order to lodge and execute your voting- instructions in this market. Absence of a poa, may cause your instructions to-be rejected. If you have any questions, please contact your client service- representative | Non-Voting | N/A | N/A |
| 1 | Acknowledgement and discussion of the annual report of the board of directors- relating to the non-consolidated and consolidated annual accounts of the- company for the financial year ended on 31 december 2017, and of the report-of the statutory auditor relating to the non-consolidated annual accounts of-the company for the financial year ended on 31 december 2017 | Non-Voting | N/A | N/A |
| 2 | Acknowledgement and approval of the non-consolidated annual accounts of the company for the financial year ended on 31 december 2017 and approval of the allocation of the annual result as proposed by the board of directors | Management | For | For |
| 3 | Acknowledgement and discussion of the report of the statutory auditor-relating to the consolidated annual accounts of the company for the financial-year ended on 31 december 2017 | Non-Voting | N/A | N/A |
| 4 | Acknowledgement and discussion of the consolidated annual accounts of the- company for the financial year ended on 31 december 2017 | Non-Voting | N/A | N/A |
| 5 | Acknowledgement and approval of the remuneration report | Management | For | For |
| 6 | Release from liability to be granted to the directors and the statutory auditor for the performance of their duties in the course of the financial year ended 31 december 2017 | Management | For | For |
| 7.I | The shareholders meeting resolves to re- appoint dr. werner cautreels (residing in boston, ma, united states of america) as director of the company, for a period of one year ending immediately after the annual shareholders meeting to be held in 2019 | Management | For | For |
| 7.II | The shareholders meeting resolves to re- appoint mr. howard rowe (residing in london, united kingdom) as director of the company, for a period of four years ending immediately after the annual shareholders meeting to be held in 2022 and, upon the proposal of the board of directors and in accordance with the advice of the company s nomination and remuneration committee, to | Management | For | For |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

appoint mr. rowe as an independent director as he meets
the independence criteria set forth in article 526ter of the
belgian companies code

| | | | | |
|----|---------------------------|------------|-----|-----|
| 8 | Remuneration of directors | Management | For | For |
| 9 | Offer of warrants | Management | For | For |
| 10 | Miscellaneous | Non-Voting | N/A | N/A |

GENOMEDX BIOSCIENCES, INC.

| | | | |
|----------------------|-----|---------------------|-------------|
| Security | N/A | Meeting Type | Special |
| Ticker Symbol | N/A | Meeting Date | 20-Nov-2017 |
| Record Date | N/A | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|-------------|---|--------------------|-------------|-------------------------------|
| 1. | Authorized Share Structure Amendment Resolution | Management | For | For |
| 2. | Special Rights and Restrictions Resolution | Management | For | For |
| 3. | Class C Preferred Share Issuance Resolution | Management | For | For |

GENOMEDX BIOSCIENCES, INC.

| | | | |
|----------------------|-----|---------------------|------------|
| Security | N/A | Meeting Type | Special |
| Ticker Symbol | N/A | Meeting Date | 8-Jan-2018 |
| Record Date | N/A | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|-------------|---|--------------------|-------------|-------------------------------|
| 1. | Non-shareholders as Proxyholders Resolution | Management | For | For |
| 2. | Special Rights and Restrictions Resolution | Management | For | For |

GENOMEDX BIOSCIENCES, INC.

| | | | |
|----------------------|-----|---------------------|------------|
| Security | N/A | Meeting Type | Special |
| Ticker Symbol | N/A | Meeting Date | 4-Feb-2018 |
| Record Date | N/A | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|-------------|---|--------------------|-------------|-------------------------------|
| 1. | Non-shareholders as Proxyholders Resolution | Management | For | For |
| 2. | Authorized Share Structure Amendment Resolution | Management | For | For |
| 3. | Articles Amendment Resolution | Management | For | For |
| 4. | New Preferred Share Issuance Resolution | Management | For | For |

GENOMEDX BIOSCIENCES, INC.

| | | | |
|----------------------|-----|---------------------|-------------|
| Security | N/A | Meeting Type | Special |
| Ticker Symbol | N/A | Meeting Date | 31-Mar-2018 |
| Record Date | N/A | | |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1. | Non-shareholders as Proxyholders Resolution | Management | For | For |
| 2. | Authorized Share Structure Amendment Resolution | Management | For | For |
| 3. | Articles Amendment Resolution | Management | For | For |
| 4. | New Preferred Share Issuance Resolution | Management | For | For |

GENOMEDX BIOSCIENCES, INC.

| | | | |
|----------------------|-----|---------------------|------------|
| Security | N/A | Meeting Type | Special |
| Ticker Symbol | N/A | Meeting Date | 9-Jul-2018 |
| Record Date | N/A | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1. | Non-shareholders as Proxyholders Resolution | Management | For | For |
| 2. | Domestication Resolution | Management | For | For |

GILEAD SCIENCES, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 375558103 | Meeting Type | Annual |
| Ticker Symbol | GILD | Meeting Date | 09-May-2018 |
| Record Date | 16-Mar-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------|---------|------------------------|
| 1a. | Election of Director: John F. Cogan, Ph.D. | Management | For | For |
| 1b. | Election of Director: Jacqueline K. Barton, Ph.D. | Management | For | For |
| 1c. | Election of Director: Kelly A. Kramer | Management | For | For |
| 1d. | Election of Director: Kevin E. Lofton | Management | For | For |
| 1e. | Election of Director: John C. Martin, Ph.D. | Management | For | For |
| 1f. | Election of Director: John F. Milligan, Ph.D. | Management | For | For |
| 1g. | Election of Director: Richard J. Whitley, M.D. | Management | For | For |
| 1h. | Election of Director: Gayle E. Wilson | Management | For | For |
| 1i. | Election of Director: Per Wold-Olsen | Management | For | For |
| 2. | To ratify the selection of Ernst & Young LLP by the Audit Committee of the Board of Directors as the independent registered public accounting firm of Gilead for the fiscal year ending December 31, 2018. | Management | For | For |
| 3. | To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement. | Management | For | For |
| 4. | To vote on a stockholder proposal, if properly presented at the meeting, requesting that the Board adopt a policy that the Chairman of the Board of Directors be an independent director. | Shareholder | Against | For |
| 5. | To vote on a stockholder proposal, if properly presented at the meeting, requesting that the Board take steps to permit stockholder action by written consent. | Shareholder | Against | For |

GLAUKOS CORPORATION

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 377322102 | Meeting Type | Annual |
| Ticker Symbol | GKOS | Meeting Date | 31-May-2018 |
| Record Date | 05-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------|--------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 Thomas W. Burns | | For | For |
| | 2 Gilbert H. Kliman, M.D. | | For | For |
| | 3 Marc A. Stapley | | For | For |
| 2. | Approval, on an advisory basis, of the compensation of the Company's named executive officers. | Management | For | For |
| 3. | Approval, on an advisory basis, of the frequency of future advisory votes on executive compensation. | Management | 1 Year | For |
| 4. | Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2018. | Management | For | For |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

GLOBAL BLOOD THERAPEUTICS, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 37890U108 | Meeting Type | Annual |
| Ticker Symbol | GBT | Meeting Date | 20-Jun-2018 |
| Record Date | 23-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------|--------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 Scott W. Morrison | | For | For |
| | 2 Deval L. Patrick | | For | For |
| | 3 Mark L. Perry | | For | For |
| 2. | Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers as disclosed in the proxy statement. | Management | For | For |
| 3. | Recommendation, on a non-binding, advisory basis, of the preferred frequency of future advisory votes on the compensation of the Company's named executive officers. | Management | 1 Year | For |
| 4. | Ratification of the appointment of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2018. | Management | For | For |
| 5. | Transaction of such other business as may properly come before the meeting or any adjournment or postponement thereof. | Management | For | For |

GW PHARMACEUTICALS PLC

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 36197T103 | Meeting Type | Annual |
| Ticker Symbol | GWPH | Meeting Date | 14-Mar-2018 |
| Record Date | 05-Feb-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| O1 | TO RECEIVE, CONSIDER AND ADOPT THE DIRECTORS' AND AUDITORS' REPORTS AND STATEMENT OF ACCOUNTS FOR THE YEAR ENDED 30 SEPTEMBER 2017 AND NOTE THAT THE DIRECTORS DO NOT RECOMMEND PAYMENT OF A DIVIDEND | Management | For | N/A |
| O2 | TO APPROVE THE DIRECTORS' REMUNERATION REPORT | Management | For | N/A |
| O3 | TO APPROVE THE DIRECTORS' REMUNERATION POLICY | Management | For | N/A |
| O4 | TO RE-ELECT JUSTIN GOVER AS A DIRECTOR | Management | For | N/A |
| O5 | TO ELECT CATHERINE MACKEY AS A DIRECTOR | Management | For | N/A |
| O6 | TO ELECT ALICIA SECOR AS A DIRECTOR | Management | For | N/A |
| O7 | TO ELECT WILLIAM WALDEGRAVE AS A DIRECTOR | Management | For | N/A |
| O8 | TO RE-APPOINT DELOITTE LLP AS AUDITOR | Management | For | N/A |
| O9 | To authorise the Directors to determine the Auditor's remuneration | Management | For | N/A |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| | | | | |
|-----|---|------------|-----|-----|
| O10 | To authorise the Directors to allot shares pursuant to Section 551 of the Companies Act 2006 (the 2006 Act) | Management | For | N/A |
| S11 | Subject to the passing of Resolution 10, to authorise the ...(due to space limits, see proxy material for full proposal). | Management | For | N/A |
| S12 | To adopt new articles of association of the Company in ...(due to space limits, see proxy material for full proposal). | Management | For | N/A |

IDEXX LABORATORIES, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 45168D104 | Meeting Type | Annual |
| Ticker Symbol | IDXX | Meeting Date | 09-May-2018 |
| Record Date | 16-Mar-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|-------------|---|--------------------|-------------|-------------------------------|
| 1a. | Election of Director: Bruce L. Claflin | Management | For | For |
| 1b. | Election of Director: Daniel M. Junius | Management | For | For |
| 2. | Ratification of Appointment of Independent Registered Public Accounting Firm. To ratify the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the current fiscal year. | Management | For | For |
| 3. | Approval of the Adoption of the IDEXX Laboratories, Inc. 2018 Incentive Plan. To approve the Company's 2018 Stock Incentive Plan. | Management | For | For |
| 4. | Advisory Vote on Executive Compensation. To approve a nonbinding advisory resolution on the Company's executive compensation. | Management | For | For |

ILLUMINA, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 452327109 | Meeting Type | Annual |
| Ticker Symbol | ILMN | Meeting Date | 23-May-2018 |
| Record Date | 29-Mar-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|-------------|---|--------------------|-------------|-------------------------------|
| 1a. | Election of Director: Jay T. Flatley | Management | For | For |
| 1b. | Election of Director: John W. Thompson | Management | For | For |
| 1c. | Election of Director: Gary S. Guthart, Ph.D. | Management | For | For |
| 2. | To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 30, 2018. | Management | For | For |
| 3. | To approve, on an advisory basis, the compensation of the named executive officers as disclosed in the Proxy Statement. | Management | For | For |
| 4. | To approve, on an advisory basis, a stockholder proposal to elect each director annually. | Shareholder | Against | For |

ILLUMINOSS MEDICAL, INC.

| | | | |
|----------------------|-----|---------------------|-----------------|
| Security | N/A | Meeting Type | Written Consent |
| Ticker Symbol | N/A | Meeting Date | 14-Nov-2017 |
| Record Date | N/A | | |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| Item | Proposal | Proposed by | Vote | For/Against Management |
|-------------|---|------------------------|-------------|-----------------------------------|
| 1. | Sixth Amended and Restated Certificate of Incorporation | Management | For | For |
| 2. | Convertible Note Financing | Management | For | For |
| 3. | Amendment of March 2017 Notes and Warrants | Management | For | For |
| 4. | Anti-Dilution | Management | For | For |
| 5. | General Resolutions | Management | For | For |

INCYTE CORPORATION

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 45337C102 | Meeting Type | Annual |
| Ticker Symbol | INCY | Meeting Date | 01-May-2018 |
| Record Date | 05-Mar-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1.1 | Election of Director: Julian C. Baker | Management | For | For |
| 1.2 | Election of Director: Jean-Jacques Bienaime | Management | For | For |
| 1.3 | Election of Director: Paul A. Brooke | Management | For | For |
| 1.4 | Election of Director: Paul J. Clancy | Management | For | For |
| 1.5 | Election of Director: Wendy L. Dixon | Management | For | For |
| 1.6 | Election of Director: Jacquelyn A. Fouse | Management | For | For |
| 1.7 | Election of Director: Paul A. Friedman | Management | For | For |
| 1.8 | Election of Director: Herve Hoppenot | Management | For | For |
| 2. | To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers. | Management | For | For |
| 3. | To approve amendments to the Company's Amended and Restated 2010 Stock Incentive Plan. | Management | For | For |
| 4. | To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for 2018. | Management | For | For |

INNOVIVA INC

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 45781M101 | Meeting Type | Annual |
| Ticker Symbol | INVA | Meeting Date | 24-Apr-2018 |
| Record Date | 19-Mar-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1a. | Election of Director: George W. Bickerstaff, III | Management | For | For |
| 1b. | Election of Director: Mark DiPaolo, Esq. | Management | For | For |
| 1c. | Election of Director: Jules Haimovitz | Management | For | For |
| 1d. | Election of Director: Odysseas D. Kostas, M.D. | Management | For | For |
| 1e. | Election of Director: Sarah Schlesinger, M.D. | Management | For | For |
| 2. | Approve the non-binding advisory resolution regarding executive compensation. | Management | For | For |
| 3. | Ratify the selection by the Audit Committee of the Board of Directors for Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management | For | For |

INTELLIA THERAPEUTICS, INC.

| | | | |
|-----------------|-----------|---------------------|--------|
| Security | 45826J105 | Meeting Type | Annual |
|-----------------|-----------|---------------------|--------|

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

Ticker Symbol NTLA **Meeting Date** 17-May-2018
Record Date 04-Apr-2018

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1a. | Election of Class II Director: Frank Verwiel | Management | For | For |
| 2. | Ratification of the appointment of Deloitte & Touche LLP as Intellia's independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management | For | For |

IONIS PHARMACEUTICALS, INC.

Security 462222100 **Meeting Type** Annual
Ticker Symbol IONS **Meeting Date** 23-May-2018
Record Date 26-Mar-2018

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 Frederick T. Muto | | For | For |
| | 2 Breaux B. Castleman | | For | For |
| 2. | To approve, by non-binding vote, executive compensation. | Management | For | For |
| 3. | Ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2018 fiscal year. | Management | For | For |

JAZZ PHARMACEUTICALS PLC

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | G50871105 | Meeting Type | Annual |
| Ticker Symbol | JAZZ | Meeting Date | 02-Aug-2018 |
| Record Date | 06-Jun-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---|-------------|--------|------------------------|
| 1a. | Election of Director: Peter Gray | Management | For | For |
| 1b. | Election of Director: Kenneth W. O Keefe | Management | For | For |
| 1c. | Election of Director: Elmar Schnee | Management | For | For |
| 1d. | Election of Director: Catherine A. Sohn | Management | For | For |
| 2. | To ratify, on a non-binding advisory basis, the appointment of KPMG, Dublin as the independent auditors of Jazz Pharmaceuticals plc for the fiscal year ending December 31, 2018 and to authorize, in a binding vote, the board of directors, acting through the audit committee, to determine the independent auditors remuneration. | Management | For | For |
| 3. | To approve, on a non-binding advisory basis, the compensation of Jazz Pharmaceuticals plc s named executive officers as disclosed in the proxy statement. | Management | For | For |
| 4. | To indicate, on a non-binding advisory basis, the preferred frequency of the advisory vote on the compensation of Jazz Pharmaceuticals plc s named executive officers. | Management | 1 Year | For |

JOUNCE THERAPEUTICS, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 481116101 | Meeting Type | Annual |
| Ticker Symbol | JNCE | Meeting Date | 19-Jun-2018 |
| Record Date | 23-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 J. Duncan Higgons | | For | For |
| | 2 Robert Tepper, M.D. | | For | For |
| 2. | Ratification of the selection of Ernst & Young LLP as the Company s independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management | For | For |

LEXICON PHARMACEUTICALS, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 528872302 | Meeting Type | Annual |
| Ticker Symbol | LXX | Meeting Date | 26-Apr-2018 |
| Record Date | 26-Feb-2018 | | |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---|---------------------|------|------------------------|
| 1. | DIRECTOR | | | |
| | 1 | Philippe J. Amouyal | For | For |
| | 2 | Lonnell Coats | For | For |
| | 3 | Frank P. Palantoni | For | For |
| 2. | Advisory vote to approve the compensation paid to the Company's named executive officers. | Management | For | For |
| 3. | Ratification and approval of the appointment of Ernst & Young LLP as Company's independent auditors for the fiscal year ending December 31, 2018. | Management | For | For |

MILESTONE PHARMACEUTICALS INC.

| | | | |
|----------------------|-----|---------------------|-------------|
| Security | N/A | Meeting Type | Annual |
| Ticker Symbol | N/A | Meeting Date | 27-Jun-2018 |
| Record Date | N/A | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1. | Acceptance of the Audited Financial Statements of the Corporation for year ended December 31, 2017 | Management | For | For |
| 2. | Election of Directors | Management | For | For |
| 3. | Appointment of Auditors | Management | For | For |
| 4. | Transaction of other Business | Management | For | For |

MOLECULAR TEMPLATES, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 608550109 | Meeting Type | Annual |
| Ticker Symbol | MTEM | Meeting Date | 31-May-2018 |
| Record Date | 10-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 Jonathan Lanfear | | For | For |
| | 2 Scott Morenstein | | For | For |
| 2. | Approve the 2018 Equity Incentive Plan. | Management | For | For |
| 3. | Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending 2018. | Management | For | For |
| 4. | Approve by an advisory vote the compensation of our named executive officers, as disclosed in the accompanying proxy statement. | Management | For | For |

MYLAN N.V.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | N59465109 | Meeting Type | Annual |
| Ticker Symbol | MYL | Meeting Date | 29-Jun-2018 |
| Record Date | 01-Jun-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1A. | Appointment of Director: Heather Bresch | Management | For | For |
| 1B. | Appointment of Director: Hon. Robert J. Cindrich | Management | For | For |
| 1C. | Appointment of Director: Robert J. Coury | Management | For | For |
| 1D. | Appointment of Director: JoEllen Lyons Dillon | Management | For | For |
| 1E. | Appointment of Director: Neil Dimick, C.P.A. | Management | For | For |
| 1F. | Appointment of Director: Melina Higgins | Management | For | For |
| 1G. | Appointment of Director: Harry A. Korman | Management | For | For |
| 1H. | Appointment of Director: Rajiv Malik | Management | For | For |
| 1I. | Appointment of Director: Mark W. Parrish | Management | For | For |
| 1J. | Appointment of Director: Pauline van der Meer Mohr | Management | For | For |
| 1K. | Appointment of Director: Randall L. (Pete) Vanderveen, Ph.D. | Management | For | For |
| 1L. | Appointment of Director: Sjoerd S. Vollebregt | Management | For | For |
| 2. | Approval, on an advisory basis, of the compensation of the named executive officers of the Company | Management | For | For |
| 3. | Adoption of the Dutch annual accounts for fiscal year 2017 | Management | For | For |
| 4. | Ratification of the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for fiscal year 2018 | Management | For | For |
| 5. | Instruction to Deloitte Accountants B.V. for the audit of the Company's Dutch statutory annual accounts for fiscal year 2018 | Management | For | For |
| 6. | | Management | For | For |

Authorization of the Board to acquire shares in the capital
of the Company

MYOVANT SCIENCES LTD.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | G637AM102 | Meeting Type | Annual |
| Ticker Symbol | MYOV | Meeting Date | 18-Aug-2017 |
| Record Date | 14-Jul-2017 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1.1 | ELECTION OF CLASS I DIRECTOR: MARK ALTMAYER | Management | For | For |
| 1.2 | ELECTION OF CLASS I DIRECTOR: TERRIE CURRAN | Management | For | For |
| 1.3 | ELECTION OF CLASS I DIRECTOR: KEITH MANCHESTER, M.D. | Management | For | For |
| 2. | TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF ERNST & YOUNG LLP AS MYOVANT S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR MYOVANT S FISCAL YEAR ENDING MARCH 31, 2018, TO APPOINT ERNST & YOUNG LLP AS AUDITOR FOR STATUTORY PURPOSES UNDER THE BERMUDA COMPANIES ACT 1981, AS AMENDED, FOR MYOVANT S ...(DUE TO SPACE LIMITS, SEE PROXY STATEMENT FOR FULL PROPOSAL). | Management | For | For |

MYOVANT SCIENCES LTD.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | G637AM102 | Meeting Type | Special |
| Ticker Symbol | MYOV | Meeting Date | 09-Feb-2018 |
| Record Date | 22-Jan-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1. | To approve an amendment to our Bye-laws to declassify the Board of Directors. | Management | For | For |
| 2. | To approve an amendment to our Bye-laws to modify shareholder proposal and nomination procedures. | Management | For | For |
| 3. | To approve an amendment to our Bye-laws to eliminate all supermajority voting requirements. | Management | For | For |
| 4. | To approve an amendment to our Bye-laws to modify certain director removal and vacancy requirements. | Management | For | For |
| 5. | To approve an amendment to our Bye-laws to revise certain other provisions in our Bye-laws. | Management | For | For |

NABRIVA THERAPEUTICS PLC

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | G63637105 | Meeting Type | Special |
| Ticker Symbol | NBRV | Meeting Date | 15-Sep-2017 |
| Record Date | 04-Aug-2017 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1.1 | ELECTION OF DIRECTOR TO SERVE UNTIL THE 2018 ANNUAL GENERAL MEETING: DANIEL BURGESS | Management | For | For |
| 1.2 | ELECTION OF DIRECTOR TO SERVE UNTIL THE 2018 ANNUAL GENERAL MEETING: AXEL BOLTE | Management | For | For |
| 1.3 | ELECTION OF DIRECTOR TO SERVE UNTIL THE 2018 ANNUAL GENERAL MEETING: CARRIE BOURDOW | Management | For | For |
| 1.4 | ELECTION OF DIRECTOR TO SERVE UNTIL THE 2018 ANNUAL GENERAL MEETING: COLIN BROOM | Management | For | For |
| 1.5 | ELECTION OF DIRECTOR TO SERVE UNTIL THE 2018 ANNUAL GENERAL MEETING: MARK CORRIGAN | Management | For | For |
| 1.6 | ELECTION OF DIRECTOR TO SERVE UNTIL THE 2018 ANNUAL GENERAL MEETING: CHARLES A. ROWLAND, JR. | Management | For | For |
| 1.7 | ELECTION OF DIRECTOR TO SERVE UNTIL THE 2018 ANNUAL GENERAL MEETING: GEORGE H. TALBOT | Management | For | For |
| 1.8 | ELECTION OF DIRECTOR TO SERVE UNTIL THE 2018 ANNUAL GENERAL MEETING: STEPHEN WEBSTER | Management | For | For |
| 2. | TO RATIFY THE SELECTION OF KPMG LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017. | Management | For | For |
| 3. | TO APPROVE THE ADOPTION OF THE COMPANY S 2017 SHARE INCENTIVE PLAN. | Management | For | For |

NANOSTRING TECHNOLOGIES, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 63009R109 | Meeting Type | Annual |
| Ticker Symbol | NSTG | Meeting Date | 12-Jun-2018 |
| Record Date | 13-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|----------|------------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 | Elisha W. Finney | For | For |
| | 2 | Gregory Norden | For | For |
| | 3 | Charles P. Waite | For | For |
| 2. | | Management | For | For |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2018.

NATERA, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 632307104 | Meeting Type | Annual |
| Ticker Symbol | NTRA | Meeting Date | 16-May-2018 |
| Record Date | 26-Mar-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|-------------|--|--------------------|-------------|-------------------------------|
| 1. | DIRECTOR | | | |
| | 1 | Roelof F. Botha | For | For |
| | 2 | Todd Cozzens | For | For |
| | 3 | Matthew Rabinowitz | For | For |
| 2. | Proposal to ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management | For | For |

NEKTAR THERAPEUTICS

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 640268108 | Meeting Type | Annual |
| Ticker Symbol | NKTR | Meeting Date | 26-Jun-2018 |
| Record Date | 27-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1a. | Election of Director: Jeff Ajer | Management | For | For |
| 1b. | Election of Director: Robert B. Chess | Management | For | For |
| 1c. | Election of Director: Roy A. Whitfield | Management | For | For |
| 2. | To approve an amendment and restatement of the 2017 Performance Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under the 2017 Performance Incentive Plan by 10,900,000 shares to a total reserve of 19,200,000 shares. | Management | For | For |
| 3. | To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management | For | For |
| 4. | To approve a non-binding advisory resolution regarding our executive compensation (a say-on-pay vote). | Management | For | For |

NEUROCRINE BIOSCIENCES, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 64125C109 | Meeting Type | Annual |
| Ticker Symbol | NBIX | Meeting Date | 24-May-2018 |
| Record Date | 29-Mar-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------|---------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 William H Rastetter PhD | | For | For |
| | 2 George J. Morrow | | For | For |
| 2. | Advisory vote to approve the compensation paid to the Company's named executive officers. | Management | For | For |
| 3. | To approve an amendment to the Company's 2011 Equity Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder from 17,000,000 to 19,000,000. | Management | For | For |
| 4. | To approve the Company's 2018 Employee Stock Purchase Plan. | Management | Against | Against |
| 5. | To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management | For | For |

NEWLINK GENETICS CORPORATION

| | | | |
|----------------------|-----------|---------------------|-------------|
| Security | 651511107 | Meeting Type | Annual |
| Ticker Symbol | NLNK | Meeting Date | 23-May-2018 |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

Record Date 26-Mar-2018

| Item | Proposal | Proposed by | Vote | For/Against Management |
|-------------|--|-------------------------|-------------|-------------------------------|
| 1. | DIRECTOR | | | |
| | 1 | Chad A. Johnson | For | For |
| | 2 | Ernest J. Talarico, III | For | For |
| | 3 | Lota S. Zoth | For | For |
| 2. | To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement. | Management | For | For |
| 3. | To indicate, on an advisory basis, the preferred frequency of future advisory votes on the compensation of our named executive officers. | Management | 1 Year | For |
| 4. | To ratify the selection, by the Audit Committee of the Board of Directors, of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2018. | Management | For | For |

NOVAVAX, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 670002104 | Meeting Type | Annual |
| Ticker Symbol | NVAX | Meeting Date | 14-Jun-2018 |
| Record Date | 18-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 | Richard H. Douglas Ph.D | For | For |
| | 2 | Gary C. Evans | For | For |
| 2. | To consider and vote whether to approve, on an advisory basis, the compensation paid to our Named Executive Officers. | Management | For | For |
| 3. | To amend and restate the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, to increase the number of shares of the Company's common stock, par value \$0.01, available for issuance thereunder by 20,000,000 shares. | Management | For | For |
| 4. | To amend and restate the Novavax, Inc. Amended and Restated 2013 Employee Stock Purchase Plan, to increase the number of shares of the Company's common stock, par value \$0.01, available for issuance thereunder by 4,000,000 shares. | Management | For | For |
| 5. | To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management | For | For |

NUCANA PLC

| | | | |
|---|----------------------------------|----------------------------------|-----------------------|
| Security Ticker Symbol Record Date | 67022C106 NCNA 24-May-2018 | Meeting Type Meeting Date | Annual 27-Jun-2018 |
|---|----------------------------------|----------------------------------|-----------------------|

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| O1 | To re-elect (as a Class III director) Isaac Cheng, who is retiring in accordance with the Articles of Association of the Company, as a director of the Company. | Management | For | N/A |
| O2 | To re-elect (as a Class III director) Martin Mellish, who is retiring by rotation in accordance with the Articles of Association of the Company, as a director of the Company. | Management | For | N/A |
| O3 | To re-elect (as a Class III director) Adam George, who is retiring by rotation in accordance with the Articles of Association of the Company, as a director of the Company. | Management | For | N/A |
| O4 | To elect (as a Class II director) Cyrille Leperlier, who is standing for election for the remaining portion of his term of office, as a director of the Company. | Management | For | N/A |
| O5 | To re-appoint Ernst & Young LLP as auditors of the Company to hold office from the conclusion of this meeting until the conclusion of the next annual general meeting of the Company. | Management | For | N/A |
| O6 | To authorise the directors to determine the remuneration of the auditors of the Company. | Management | For | N/A |
| O7 | To receive the Company's audited accounts for the financial year ended 31 December 2017, together with the strategic report, directors' report and auditors' report on those accounts. | Management | For | N/A |
| O8 | To receive and approve the Directors' Remuneration Report (other than the part containing the Directors' Remuneration Policy) for the financial year ended 31 December 2017. | Management | For | N/A |
| O9 | To receive and approve the Directors' Remuneration Policy, such policy to take effect from the date on which this resolution is passed. | Management | For | N/A |
| O10 | That the directors be generally and unconditionally authorised pursuant to Section 551 of the Companies Act 2006 (the Act) to exercise all the powers of the Company to allot shares in the Company or grant rights to subscribe for or to convert any security into shares in the Company up to an aggregate nominal amount of GBP 640,000. This authority shall, unless previously renewed, revoked or varied by the Company in general meeting, expire on the conclusion of the annual general meeting ...(due to space limits, see proxy material for full proposal). | Management | For | N/A |
| S11 | That, subject to the passing of resolution 10, the directors be empowered pursuant to Section 570 of the Act to allot equity securities (as defined in Section 560 of the Act) for cash under the authority given by that resolution as if Section 561 (1) of the Act did not apply to any such allotment, provided that such authority shall be limited to the allotment of equity securities up to a nominal amount of GBP 640,000, such authority to expire on the conclusion of the annual general ...(due to space limits, see proxy | Management | For | N/A |

material for full proposal).

OVID THERAPEUTICS INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 690469101 | Meeting Type | Annual |
| Ticker Symbol | OVID | Meeting Date | 06-Jun-2018 |
| Record Date | 11-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|-------------|---|--------------------|-------------|-------------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 Douglas Williams | | For | For |
| | 2 Barbara Duncan | | For | For |
| 2. | Ratification of the selection of the independent registered public accounting firm. | Management | For | For |

PIERIS PHARMACEUTICALS, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 720795103 | Meeting Type | Annual |
| Ticker Symbol | PIRS | Meeting Date | 24-Jul-2018 |
| Record Date | 25-May-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|------------------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 | Christopher P. Kiritsy | For | For |
| | 2 | Jean-Pierre Bizzari | For | For |
| 2. | Approve the Company's 2018 Employee, Director and Consultant Equity Incentive Plan. | Management | For | For |
| 3. | Approve the Company's 2018 Employee Stock Purchase Plan. | Management | For | For |
| 4. | Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management | For | For |

PORTOLA PHARMACEUTICALS, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 737010108 | Meeting Type | Annual |
| Ticker Symbol | PTLA | Meeting Date | 08-Jun-2018 |
| Record Date | 12-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---|----------------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 | Dennis Fenton, Ph.D. | For | For |
| | 2 | Charles Homcy, M.D. | For | For |
| | 3 | David C. Stump, M.D. | For | For |
| 2. | To approve an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended, to increase the authorized number of shares of common stock from 100,000,000 to 150,000,000 shares. | Management | For | For |
| 3. | To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in this proxy statement. | Management | For | For |
| 4. | To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management | For | For |

PROTAGONIST THERAPEUTICS INC

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 74366E102 | Meeting Type | Annual |
| Ticker Symbol | PTGX | Meeting Date | 29-May-2018 |
| Record Date | 09-Apr-2018 | | |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---|-------------------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 | Chaitan Khosla, Ph.D. | For | For |
| | 2 | William D. Waddill | For | For |
| | 3 | Lewis T Williams MD PhD | For | For |
| 2. | To ratify the selection by the Audit Committee of the Board of PricewaterhouseCoopers LLP as Protagonist Therapeutics independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management | For | For |

PTC THERAPEUTICS, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 69366J200 | Meeting Type | Annual |
| Ticker Symbol | PTCT | Meeting Date | 13-Jun-2018 |
| Record Date | 20-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---|-------------------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 | Michael Schmertzler | For | For |
| | 2 | G D Steele Jr., MD, PhD | For | For |
| 2. | Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management | For | For |
| 3. | Advisory vote to approve named executive officer compensation. | Management | For | For |

PUMA BIOTECHNOLOGY, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 74587V107 | Meeting Type | Annual |
| Ticker Symbol | PBYI | Meeting Date | 12-Jun-2018 |
| Record Date | 20-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-----------------------|--------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 | Alan H. Auerbach | For | For |
| | 2 | Michael P. Miller | For | For |
| | 3 | Jay M. Moyes | For | For |
| | 4 | Adrian M. Senderowicz | For | For |
| | 5 | Troy E. Wilson | For | For |
| | 6 | Frank E. Zavr1 | For | For |
| 2. | Ratification of the selection of KPMG LLP as independent registered public accounting firm of Puma Biotechnology, Inc. for the fiscal year ending December 31, 2018. | Management | For | For |
| 3. | Advisory (non-binding) vote to approve the compensation of Puma Biotechnology, Inc.'s named executive officers. | Management | For | For |
| 4. | Advisory (non-binding) vote to approve the frequency of future votes on Puma Biotechnology, Inc.'s executive compensation. | Management | 1 Year | For |

RA PHARMACEUTICALS, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 74933V108 | Meeting Type | Annual |
| Ticker Symbol | RARX | Meeting Date | 28-Jun-2018 |
| Record Date | 30-Apr-2018 | | |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---|--------------------|------|------------------------|
| 1. | DIRECTOR | | | |
| | 1 | Robert Heft, Ph.D. | For | For |
| | 2 | Rajeev Shah | For | For |
| 2. | To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management | For | For |

REGENERON PHARMACEUTICALS, INC.

| | | | |
|-------------------------------|-------------------|---------------------|-------------|
| Security Ticker Symbol | 75886F107 REGN | Meeting Type | Annual |
| Record Date | 12-Apr-2018 | Meeting Date | 08-Jun-2018 |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1.1 | Election of Director: Arthur F. Ryan | Management | For | For |
| 1.2 | Election of Director: George L. Sing | Management | For | For |
| 1.3 | Election of Director: Marc Tessier-Lavigne | Management | For | For |
| 2. | Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management | For | For |

REVANCE THERAPEUTICS, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 761330109 | Meeting Type | Annual |
| Ticker Symbol | RVNC | Meeting Date | 10-May-2018 |
| Record Date | 13-Mar-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1a. | Election of Director: Angus C. Russell | Management | For | For |
| 1b. | Election of Director: Phyllis Gardner, M.D. | Management | For | For |
| 1c. | Election of Director: Julian S. Gangolli | Management | For | For |
| 2. | Ratification of the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year 2018. | Management | For | For |

SAGE THERAPEUTICS, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 78667J108 | Meeting Type | Annual |
| Ticker Symbol | SAGE | Meeting Date | 06-Jun-2018 |
| Record Date | 09-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|--------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 | Geno Germano | For | For |
| | 2 | Steven Paul | For | For |
| 2. | To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management | For | For |
| 3. | Approve, on an advisory basis, the compensation of the named executive officers. | Management | For | For |

SAREPTA THERAPEUTICS INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 803607100 | Meeting Type | Annual |
| Ticker Symbol | SRPT | Meeting Date | 06-Jun-2018 |
| Record Date | 11-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1A | ELECTION OF GROUP I DIRECTOR: Michael W. Bonney | Management | For | For |
| 1B | ELECTION OF GROUP I DIRECTOR: Douglas S. Ingram | Management | For | For |
| 1C | ELECTION OF GROUP I DIRECTOR: Hans Wigzell, M.D., Ph.D. | Management | For | For |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| | | | | |
|----|---|------------|-----|-----|
| 2. | ADVISORY VOTE TO APPROVE, ON A NON-BINDING BASIS, NAMED EXECUTIVE OFFICER COMPENSATION | Management | For | For |
| 3. | APPROVAL OF THE COMPANY'S 2018 EQUITY INCENTIVE PLAN | Management | For | For |
| 4. | RATIFICATION OF KPMG LLP AS INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2018 | Management | For | For |

SEATTLE GENETICS, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 812578102 | Meeting Type | Annual |
| Ticker Symbol | SGEN | Meeting Date | 18-May-2018 |
| Record Date | 22-Mar-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|-------------|--|--------------------|-------------|-------------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 Clay B. Siegall | | For | For |
| | 2 Felix Baker | | For | For |
| | 3 Nancy A. Simonian | | For | For |
| 2. | To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management | For | For |
| 3. | To approve the amendment and restatement of the Seattle Genetics, Inc. Amended and Restated 2007 Equity and Incentive Plan to, among other changes, increase the aggregate number of shares of common stock authorized for issuance thereunder by 6,000,000. | Management | For | For |
| 4. | Advisory vote to approve the compensation of the Company's named executive officers as disclosed in the Company's proxy statement. | Management | For | For |

SHIRE PLC

| | | | |
|---|----------------------------------|----------------------------------|-----------------------|
| Security Ticker Symbol Record Date | 82481R106 SHPG 22-Mar-2018 | Meeting Type Meeting Date | Annual 24-Apr-2018 |
|---|----------------------------------|----------------------------------|-----------------------|

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1. | To receive the Company's Annual Report and Accounts for the year ended December 31, 2017. | Management | For | For |
| 2. | To approve the Directors' Remuneration Report, excluding the Directors' Remuneration Policy, set out on pages 78 to 108 of the Annual Report and Accounts for the year ended December 31, 2017. | Management | For | For |
| 3. | To approve the Directors' Remuneration Policy, contained within the Directors' Remuneration Report and set out on pages 86 to 95 of the Annual Report and Accounts for the year ended December 31, 2017, to take effect after the end of the Annual General Meeting on April 24, 2018. | Management | For | For |
| 4. | To re-elect Olivier Bohuon as a Director. | Management | For | For |
| 5. | To re-elect Ian Clark as a Director. | Management | For | For |
| 6. | To elect Thomas Dittrich as a Director. | Management | For | For |
| 7. | To re-elect Gail Fosler as a Director. | Management | For | For |
| 8. | To re-elect Steven Gillis as a Director. | Management | For | For |
| 9. | To re-elect David Ginsburg as a Director. | Management | For | For |
| 10. | To re-elect Susan Kilsby as a Director. | Management | For | For |
| 11. | To re-elect Sara Mathew as a Director. | Management | For | For |
| 12. | To re-elect Flemming Ornskov as a Director. | Management | For | For |
| 13. | To re-elect Albert Stroucken as a Director. | Management | For | For |
| 14. | To re-appoint Deloitte LLP as the Company's Auditor until the conclusion of the next Annual General Meeting of the Company. | Management | For | For |
| 15. | To authorize the Audit, Compliance & Risk Committee to determine the remuneration of the Auditor. | Management | For | For |
| 16. | That the authority to allot Relevant Securities (as defined in the Company's Articles of Association (the "Articles")) conferred on the Directors by Article 10 paragraph (B) of the Articles be renewed and for this purpose the Authorised Allotment Amount shall be: (a) GBP 15,187,600.85 of Relevant Securities. (b) solely in connection with an allotment pursuant to an offer by way of a Rights Issue (as defined in the Articles, but only if and to the extent that such offer is ...(due to space limits, see proxy material for full proposal). | Management | For | For |
| 17. | That, subject to the passing of Resolution 16, the authority to allot equity securities (as defined in the Company's Articles of Association (the "Articles")) wholly for cash conferred on the Directors by Article 10 paragraph (D) of the Articles be renewed and for this purpose the Non Pre-emptive Amount (as defined in the Articles) shall be GBP 2,278,140.10 and the Allotment Period shall be the period commencing on April 24, 2018, and ending on the earlier of the close of business on ...(due to space limits, see proxy material for full proposal). | Management | For | For |
| 18. | | Management | For | For |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

That, subject to the passing of Resolutions 16 and 17 and for the purpose of the authority to allot equity securities (as defined in the Company's Articles of Association (the Articles)) wholly for cash conferred on the Directors by Article 10 paragraph (D) of the Articles and renewed by Resolution 17, the Non Pre-emptive Amount (as defined in the Articles) shall be increased from GBP 2,278,140.10 to GBP ...(due to space limits, see proxy material for full proposal).

| | | | | |
|-----|---|------------|-----|-----|
| 19. | That the Company be and is hereby generally and unconditionally authorized: (a) pursuant to Article 57 of the Companies (Jersey) Law 1991 to make market purchases of Ordinary Shares in the capital of the Company, provided that: (1) the maximum number of Ordinary Shares hereby authorized to be purchased is 91,125,605; (2) the minimum price, exclusive of any expenses, which may be paid for an Ordinary Share is five pence; (3) the maximum price, exclusive of any expenses, which may be paid ...(due to space limits, see proxy material for full proposal). | Management | For | For |
| 20. | To approve that a general meeting of the Company, other than an annual general meeting, may be called on not less than 14 clear days' notice. | Management | For | For |

SPARK THERAPEUTICS, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 84652J103 | Meeting Type | Annual |
| Ticker Symbol | ONCE | Meeting Date | 30-May-2018 |
| Record Date | 09-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 Jeffrey D. Marrazzo | | For | For |
| | 2 Vincent J. Milano | | For | For |
| | 3 Elliott Sigal M.D. Ph.D | | For | For |
| 2. | To approve, on an advisory basis, the compensation paid to the Company's named executive officers. | Management | For | For |
| 3. | To ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management | For | For |

SYNDAX PHARMACEUTICALS, INC

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 87164F105 | Meeting Type | Annual |
| Ticker Symbol | SNDX | Meeting Date | 23-May-2018 |
| Record Date | 26-Mar-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1a. | Election of Director: Henry Chen | Management | For | For |
| 1b. | Election of Director: Luke Evnin, Ph.D. | Management | For | For |
| 2. | To ratify the selection of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2018. | Management | For | For |

TELIGENT, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 87960W104 | Meeting Type | Annual |
| Ticker Symbol | TLGT | Meeting Date | 21-May-2018 |
| Record Date | 29-Mar-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--------------------------|-------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 Carole S. Ben-Maimon | | For | For |
| | 2 John Celentano | | For | For |
| | 3 Bhaskar Chaudhuri | | For | For |
| | 4 James C. Gale | | For | For |
| | 5 Jason Grenfell-Gardner | | For | For |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| | | | | | |
|----|---|---|------------|-----|-----|
| | 6 | Steven Koehler | | For | For |
| | 7 | Thomas J. Sabatino, Jr. | | For | For |
| 2. | | Approve an amendment to the Teligent, Inc. 2016 Equity Incentive Plan to increase the number of shares of common stock reserved thereunder for issuance from 2,000,000 shares to a total of 4,000,000 shares. | Management | For | For |
| 3. | | To ratify the selection of EisnerAmper LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management | For | For |
| 4. | | To approve by an advisory vote the compensation of the Company's named executive officers as disclosed in the proxy statement. | Management | For | For |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

TESARO INC

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 881569107 | Meeting Type | Annual |
| Ticker Symbol | TSRO | Meeting Date | 10-May-2018 |
| Record Date | 13-Mar-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 Leon O. Moulder, Jr. | | For | For |
| | 2 Mary Lynne Hedley, Ph.D | | For | For |
| | 3 David M. Mott | | For | For |
| | 4 Lawrence M. Alleva | | For | For |
| | 5 James O. Armitage, M.D. | | For | For |
| | 6 Earl M. Collier, Jr. | | For | For |
| | 7 Garry A. Nicholson | | For | For |
| | 8 Kavita Patel, M.D. | | For | For |
| | 9 Beth Seidenberg, M.D. | | For | For |
| | 10 Pascale Witz | | For | For |
| 2. | To approve the Tesaro, Inc., Non-Employee Director Compensation Policy, including compensation amounts for 2018. | Management | For | For |
| 3. | To approve, by non-binding vote, the Company's executive compensation. | Management | For | For |
| 4. | To approve an amendment to the Tesaro, Inc., 2012 Employee Stock Purchase Plan to, among other things, increase the number of shares available for issuance thereunder by 275,000 shares. | Management | For | For |
| 5. | To ratify the appointment of Ernst & Young, LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2018. | Management | For | For |

TETRAPHASE PHARMACEUTICALS, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 88165N105 | Meeting Type | Annual |
| Ticker Symbol | TTPH | Meeting Date | 30-May-2018 |
| Record Date | 06-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 Jeffrey Chodakewitz | | For | For |
| | 2 Gerri Henwood | | For | For |
| | 3 Guy Macdonald | | For | For |
| 2. | To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management | For | For |
| 3. | To approve, on a non-binding advisory basis, the compensation of our named executive officers. | Management | For | For |

THE MEDICINES COMPANY

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 584688105 | Meeting Type | Annual |
| Ticker Symbol | MDCO | Meeting Date | 31-May-2018 |
| Record Date | 13-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|-------------|---|------------------------|-------------|-----------------------------------|
| 1A. | Election of Director: Alexander J. Denner | Management | For | For |
| 1B. | Election of Director: Fredric N. Eshelman | Management | For | For |
| 1C. | Election of Director: Geno J. Germano | Management | For | For |
| 1D. | Election of Director: John C. Kelly | Management | For | For |
| 1E. | Election of Director: Clive A. Meanwell | Management | For | For |
| 1F. | Election of Director: Paris Panayiotopoulos | Management | For | For |
| 1G. | Election of Director: Sarah J. Schlesinger | Management | For | For |
| 2. | Approve an amendment to our 2013 stock incentive plan in order to increase the number of shares of common stock authorized for issuance under the plan by 5,000,000 shares. | Management | For | For |
| 3. | Approve, in an advisory vote, the compensation of our named executive officers as presented in the proxy statement. | Management | For | For |
| 4. | Ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management | For | For |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

THERAPEUTICSMD, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 88338N107 | Meeting Type | Annual |
| Ticker Symbol | TXMD | Meeting Date | 25-Jun-2018 |
| Record Date | 26-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 Tommy G. Thompson | | For | For |
| | 2 Robert G. Finizio | | For | For |
| | 3 John C.K. Milligan, IV | | For | For |
| | 4 Brian Bernick | | For | For |
| | 5 J. Martin Carroll | | For | For |
| | 6 Cooper C. Collins | | For | For |
| | 7 Robert V. LaPenta, Jr. | | For | For |
| | 8 Jules A. Musing | | For | For |
| | 9 Angus C. Russell | | For | For |
| | 10 Jane F. Barlow | | For | For |
| | 11 Nicholas Segal | | For | For |
| 2. | To approve, on a non-binding advisory basis, the compensation of our named executive officers for the fiscal year ended December 31, 2017 (say-on-pay). | Management | For | For |
| 3. | To ratify the appointment of Grant Thornton LLP, an independent registered public accounting firm, as the independent auditor of our company for the fiscal year ending December 31, 2018. | Management | For | For |

THERAVANCE BIOPHARMA, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | G8807B106 | Meeting Type | Annual |
| Ticker Symbol | TBPH | Meeting Date | 01-May-2018 |
| Record Date | 05-Mar-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1.1 | Election of Director: Eran Broshty | Management | For | For |
| 1.2 | Election of Director: Laurie Smaldone Alsup | Management | For | For |
| 1.3 | Election of Director: Burton G. Malkiel | Management | For | For |
| 2. | Ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management | For | For |
| 3. | Adoption of the resolution approving a new shareholder rights plan and authorizing our board of directors to put the shareholder rights plan into effect in the future if and when the board of directors deems appropriate and in the best interests of the Company, which resolution is set forth as Annex A to the proxy statement. | Management | For | For |

THERMO FISHER SCIENTIFIC INC.

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 883556102 | Meeting Type | Annual |
| Ticker Symbol | TMO | Meeting Date | 23-May-2018 |
| Record Date | 28-Mar-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|-------------|---|------------------------|-------------|-----------------------------------|
| 1A. | Election of Director: Marc N. Casper | Management | For | For |
| 1B. | Election of Director: Nelson J. Chai | Management | For | For |
| 1C. | Election of Director: C. Martin Harris | Management | For | For |
| 1D. | Election of Director: Tyler Jacks | Management | For | For |
| 1E. | Election of Director: Judy C. Lewent | Management | For | For |
| 1F. | Election of Director: Thomas J. Lynch | Management | For | For |
| 1G. | Election of Director: Jim P. Manzi | Management | For | For |
| 1H. | Election of Director: Lars R. Sorensen | Management | For | For |
| 1I. | Election of Director: Scott M. Sperling | Management | For | For |
| 1J. | Election of Director: Elaine S. Ullian | Management | For | For |
| 1K. | Election of Director: Dion J. Weisler | Management | For | For |
| 2. | An advisory vote to approve named executive officer compensation. | Management | For | For |
| 3. | Ratification of the Audit Committee's selection of PricewaterhouseCoopers LLP as the Company's independent auditors for 2018. | Management | For | For |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

THEROX, INC.

| | | | |
|----------------------|-----|---------------------|-----------------|
| Security | N/A | Meeting Type | Written Consent |
| Ticker Symbol | N/A | Meeting Date | 24-Apr-2018 |
| Record Date | N/A | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---|-------------|---------|------------------------|
| 1. | Approval of Second Certificate of Amendment to Eleventh Amended and Restated Certificate of Incorporation | Management | For | For |
| 2. | Waiver of Participation Rights in Note Transaction | Management | For | For |
| 3. | Approval of Amendment to Fourth Amended and Restated Investors Rights and Voting Agreement | Management | For | For |
| 4. | Approval of Option Agreement with ZOLL | Management | For | For |
| 5. | Approval of Agreement and Plan of Merger | Management | For | For |
| 6. | Appointment of Shareholder Representative Services, LLC as Representative | Management | For | For |
| 7. | Appointment of Representative Advisory Group Members | Shareholder | Against | For |
| 8. | Ratification of Shadow Preferred Stock Issuance | Shareholder | Against | For |
| 9. | General Authority | Shareholder | Against | For |

TRILLIUM THERAPEUTICS INC.

| | | | |
|----------------------|-------------|---------------------|----------------------------|
| Security | 89620X506 | Meeting Type | Annual and Special Meeting |
| Ticker Symbol | TRIL | Meeting Date | 01-Jun-2018 |
| Record Date | 20-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------|---------|------------------------|
| 1 | DIRECTOR | Management | | |
| | 1 Mr. Luke Beshar | | For | For |
| | 2 Dr. Robert Kirkman | | For | For |
| | 3 Dr. Michael Moore | | For | For |
| | 4 Dr. Thomas Reynolds | | For | For |
| | 5 Dr. Niclas Stiernholm | | For | For |
| | 6 Dr. Calvin Stiller | | For | For |
| | 7 Dr. Helen Tayton-Martin | | For | For |
| 2 | To reappoint Ernst & Young, LLP, Chartered Professional Accountants, Licensed Public Accountants, as auditors of the Corporation for the ensuing year and to authorize the directors to fix the remuneration to be paid to the auditors. | Management | For | For |
| 3 | Consider and, if deemed appropriate, approve the Corporation's amended and restated stock option plan, all as more particularly set out in the management information circular prepared by the Corporation in respect of the Meeting. | Management | Against | Against |

ULTRAGENYX PHARMACEUTICAL INC.

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 90400D108 | Meeting Type | Annual |
| Ticker Symbol | RARE | Meeting Date | 19-Jun-2018 |
| Record Date | 23-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|-------------|---|------------------------|-------------|-----------------------------------|
| 1a. | Election of Director: Deborah Dunsire, M.D. | Management | For | For |
| 1b. | Election of Director: Michael Narachi | Management | For | For |
| 1c. | Election of Director: Clay B. Siegall, Ph.D. | Management | For | For |
| 2. | Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management | For | For |
| 3. | Advisory (non-binding) vote to approve the compensation of our named executive officers. | Management | For | For |

UNIQUE N.V.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | N90064101 | Meeting Type | Annual |
| Ticker Symbol | QURE | Meeting Date | 13-Jun-2018 |
| Record Date | 16-May-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1. | Resolution to adopt the 2017 annual accounts and treatment of the results. | Management | For | For |
| 2. | Resolution to discharge liability of the members of the Board for their management. | Management | For | For |
| 3a. | Appointment of Philip Astley-Sparke as non-executive director. | Management | For | For |
| 3b. | Appointment of Robert Gut as non-executive director. | Management | For | For |
| 3c. | Appointment of David Meek as non-executive director. | Management | For | For |
| 4. | Amendment to the 2014 Restated Plan. | Management | For | For |
| 5. | Resolution to designate the Board as the competent body to issue ordinary shares and options and to exclude preemptive rights under the 2014 Restated Plan. | Management | For | For |
| 6. | Approval of the employee share purchase plan. | Management | For | For |
| 7. | Resolution to redesignate the Board as the competent body to issue ordinary shares and options and to limit or exclude pre-emptive rights. | Management | For | For |
| 8. | Authorization of the Board to repurchase ordinary shares. | Management | For | For |
| 9. | Resolution to reappoint PricewaterhouseCoopers Accountants N.V. as auditor of the Company for the 2018 financial year ending at the close of the Annual General Meeting. | Management | For | For |

UNITED THERAPEUTICS CORPORATION

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 91307C102 | Meeting Type | Annual |
| Ticker Symbol | UTHR | Meeting Date | 26-Jun-2018 |
| Record Date | 30-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1a. | Election of Director: Katherine Klein | Management | For | For |
| 1b. | Election of Director: Ray Kurzweil | Management | For | For |
| 1c. | Election of Director: Martine Rothblatt | Management | For | For |
| 1d. | Election of Director: Louis Sullivan | Management | For | For |
| 2. | Advisory resolution to approve executive compensation. | Management | For | For |
| 3. | Approval of the amendment and restatement of the United Therapeutics Corporation 2015 Stock Incentive Plan. | Management | For | For |
| 4. | Ratification of the appointment of Ernst & Young LLP as United Therapeutics Corporation's independent registered public accounting firm for 2018. | Management | For | For |

VERONA PHARMA PLC

| | | | |
|----------------------|--------------|---------------------|------------------------|
| Security | GB00BYW2KH80 | Meeting Type | Annual General Meeting |
| Ticker Symbol | VRP | Meeting Date | 02-May-2018 |
| Record Date | N/A | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1 | TO RECEIVE AND ADOPT THE REPORT OF THE DIRECTORS AND THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2017 | Management | For | For |
| 2 | TO APPROVE THE DIRECTORS REMUNERATION POLICY | Management | For | For |
| 3 | TO APPROVE THE DIRECTORS REMUNERATION REPORT | Management | For | For |
| 4 | TO RE-ELECT DAVID RAYMOND EBSWORTH AS A DIRECTOR OF THE COMPANY | Management | For | For |
| 5 | TO RE-ELECT SVEN ANDERS ULLMAN AS A DIRECTOR OF THE COMPANY | Management | For | For |
| 6 | TO APPOINT PRICEWATERHOUSECOOPERS LLP AS AUDITORS | Management | For | For |
| 7 | TO AUTHORISE THE DIRECTORS TO DETERMINE THE AUDITORS REMUNERATION | Management | For | For |
| 8 | TO AUTHORISE THE DIRECTORS TO ALLOT RELEVANT SECURITIES PURSUANT TO SECTION 551 OF THE COMPANIES ACT 2006 | Management | For | For |
| 9 | TO AUTHORISE THE DIRECTORS TO ALLOT EQUITY SECURITIES PURSUANT TO SECTION 570 OF THE COMPANIES ACT 2006 | Management | For | For |

VERONA PHARMA PLC

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 925050106 | Meeting Type | Annual |
| Ticker Symbol | VRNA | Meeting Date | 02-May-2018 |
| Record Date | 06-Mar-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| O1 | To receive and adopt the report of the directors and the financial statements for the year ended 31 December 2017. | Management | For | For |
| O2 | To approve the Directors Remuneration Policy. | Management | For | For |
| O3 | To approve the Directors Remuneration Report. | Management | For | For |
| O4 | To re-elect David Raymond Ebsworth as a director of the Company. | Management | For | For |
| O5 | To re-elect Sven Anders Ullman as a director of the Company. | Management | For | For |
| O6 | To appoint PricewaterhouseCoopers LLP as auditors. | Management | For | For |
| O7 | To authorise the directors to determine the auditors remuneration. | Management | For | For |
| O8 | | Management | For | For |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

To authorise the directors to allot relevant securities pursuant to Section 551 of the Companies Act 2006.

| | | | | |
|----|--|------------|-----|-----|
| S9 | To authorise the directors to allot equity securities pursuant to Section 570 of the Companies Act 2006. | Management | For | For |
|----|--|------------|-----|-----|

VERONA PHARMA PLC

| | | | |
|----------------------|--------------|---------------------|--------------------------|
| Security | GB00BYW2KH80 | Meeting Type | Ordinary General Meeting |
| Ticker Symbol | VRP | Meeting Date | 26-Jun-2018 |
| Record Date | N/A | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1 | TO AUTHORISE THE DIRECTORS TO ALLOT RELEVANT SECURITIES PURSUANT TO SECTION 551 OF THE COMPANIES ACT 2006 | Management | For | For |
| 2 | TO AUTHORISE THE DIRECTORS TO ALLOT EQUITY SECURITIES AND/OR SELL TREASURY SECURITIES FOR CASH PURSUANT TO SECTION 570 AND 573 OF THE COMPANIES ACT 2006 | Management | For | For |

VERONA PHARMA PLC

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 925050106 | Meeting Type | Annual |
| Ticker Symbol | VRNA | Meeting Date | 26-Jun-2018 |
| Record Date | 24-May-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|-------------|---|--------------------|-------------|-------------------------------|
| O1. | To authorise the directors to allot relevant securities pursuant to Section 551 of the Companies Act 2006. | Management | For | For |
| S2. | To authorise the directors to allot equity securities and/or sell treasury securities for cash pursuant to Section 570 and 573 of the Companies Act 2006. | Management | For | For |

VERTEX PHARMACEUTICALS INCORPORATED

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 92532F100 | Meeting Type | Annual |
| Ticker Symbol | VRTX | Meeting Date | 17-May-2018 |
| Record Date | 29-Mar-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|-------------|---|--------------------|-------------|-------------------------------|
| 1.1 | Election of Class I Director: Sangeeta N. Bhatia | Management | For | For |
| 1.2 | Election of Class I Director: Jeffrey M. Leiden | Management | For | For |
| 1.3 | Election of Class I Director: Bruce I. Sachs | Management | For | For |
| 2. | Amendments to our charter and by-laws to eliminate supermajority provisions. | Management | For | For |
| 3. | Amendment and restatement of our 2013 Stock and Option Plan, to among other things, increase the number of shares available under the plan by 8.0 million shares. | Management | For | For |
| 4. | Ratification of Ernst & Young LLP as our Independent Registered Public Accounting firm for the year ending December 31, 2018. | Management | For | For |
| 5. | Advisory vote on named executive officer compensation. | Management | For | For |
| 6. | Shareholder proposal, if properly presented at the meeting, requesting that we prepare a report on the risks to us of rising drug prices. | Shareholder | Against | For |
| 7. | Shareholder proposal, if properly presented at the meeting, requesting that we prepare a report on our policies and activities with respect to lobbying. | Shareholder | Against | For |

XENCOR INC

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 98401F105 | Meeting Type | Annual |
| Ticker Symbol | XNCR | Meeting Date | 26-Jun-2018 |
| Record Date | 27-Apr-2018 | | |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------------------|------|------------------------|
| 1. | DIRECTOR | | | |
| | 1 | Dr. Kevin C. Gorman | For | For |
| | 2 | Dr. A. Bruce Montgomery | For | For |
| | 3 | Dr. Bassil I. Dahiyat | For | For |
| | 4 | Mr. Kurt Gustafson | For | For |
| | 5 | Mr. Yujiro S. Hata | For | For |
| | 6 | Mr. Richard Ranieri | For | For |
| 2. | Proposal to ratify RSM US LLP as the independent public accounting firm for 2018. | Management | For | For |
| 3. | Proposal to approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy materials. | Management | For | For |

XENON PHARMACEUTICALS INC

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 98420N105 | Meeting Type | Annual |
| Ticker Symbol | XENE | Meeting Date | 04-Jun-2018 |
| Record Date | 09-Apr-2018 | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|-------------|--|--------------------|-------------|-------------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 | Michael Tarnow | For | For |
| | 2 | Mohammad Azab | For | For |
| | 3 | Steven Gannon | For | For |
| | 4 | Michael Hayden | For | For |
| | 5 | Frank Holler | For | For |
| | 6 | Gary Patou | For | For |
| | 7 | Simon Pimstone | For | For |
| | 8 | Richard Scheller | For | For |
| | 9 | Dawn Svoronos | For | For |
| 2. | Appointment of KPMG LLP as Auditor | Management | For | For |
| 3. | Authorizing the Audit Committee of the board of directors of the Corporation to fix the remuneration to be paid to the Auditor | Management | For | For |

SIGNATURES

Pursuant to the requirements of the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

(Registrant) Tekla Life Sciences Investors

By (Signature and Title)*

/s/ Daniel R. Omstead
(Daniel R. Omstead, President)

Date 8/20/18

*Print the name and title of each signing officer under his or her signature.